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ABSTRACT OF DISSERTATION 
  
 
DYNAMIC L-GLUTAMATE SIGNALING IN THE PREFRONTAL CORTEX AND 
THE EFFECTS OF METHYLPHENIDATE TREATMENT 
The prefrontal cortex (PFC) is an area of the brain that is critically 
important for learning, memory, organization, and integration, and PFC 
dysfunction has been associated with pathologies including Alzheimer’s disease, 
schizophrenia, and drug addiction.  However, there exists a paucity of 
information regarding neurochemical signaling in the distinct sub-regions of the 
PFC, particularly the medial prefrontal cortex (mPFC).  The mPFC receives 
glutamatergic input from a number of brain areas, and functional glutamate 
signaling is essential for normal cognitive processes.  To further understand 
glutamate neurotransmission, in vivo measurements of glutamate were 
performed in the cingulate cortex, prelimbic cortex, and infralimbic cortex of 
anesthetized rats using enzyme-based microelectrode array technology.  
Measurements of acetylcholine were also performed to examine the relationship 
between glutamate and other neurotransmitters in the mPFC.  The described 
studies revealed a homogeneity of glutamate and acetylcholine signaling in the 
mPFC sub-regions, indicating somewhat uniform tonic and phasic levels of these 
two transmitters.  In the infralimbic mPFC of awake freely-moving rats, rapid, 
phasic glutamate signaling events, termed “transients” were observed and in vivo 
glutamate signaling was successfully monitored over 24 hour time periods. 
 
The effects of methylphenidate (MPH), a stimulant medication with abuse 
potential that is used in the treatment of attention-deficit hyperactivity disorder, 
were measured in mPFC sub-regions of anesthetized rats.  Data revealed similar 
tonic and phasic glutamate levels between chronic MPH-treated rats and controls 
in all sub-regions.  Locomotor data from the chronic treatment period supported 
the behavioral sensitization effects of multiple MPH treatments.  Significant 
effects were observed in locomotor activity, resting levels of glutamate, and 
glutamate uptake rates in the infralimbic mPFC of awake, freely-moving animals 
that received chronic MPH treatment.   
 
 
 
 
Taken together, this body of work characterizes glutamate signaling in the 
rat mPFC to a degree never before reported, and serves to report for the first 
time the effects of MPH on glutamate signaling in the mPFC.    
 
 
KEYWORDS: glutamate, prefrontal cortex, microelectrode array, 
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Chapter One: Introduction 
 
The Functions and Anatomy of the Prefrontal Cortex 
 
The term ‘prefrontal cortex’ was first used by Hines (Hines 1929) to 
describe the area of the human brain anterior to the premotor cortex, and the 
prefrontal area has been defined as the cortex “anterior to the arcuate sulcus on 
the lateral, medial, and ventral surfaces of the frontal lobe,”(Walker 1940).  In the 
human brain, the PFC encompasses Brodmann’s areas 9/46 (dorsolateral PFC) 
(Brodmann 1909; Rajkowska and Goldman-Rakic 1995) and 10 (rostral PFC) 
(Brodmann 1909; Semendeferi, Armstrong et al. 2001), as well as parts of other 
areas.  The human medial prefrontal cortex (mPFC) is specifically composed of 
areas 25, 32, and 10 (Ongur and Price 2000).  The monkey brain has similar 
boundaries, with the only difference being in the definition of Brodmann’s area 
32.  In rats, cytoarchitectural differences make it difficult to assign comparable 
mPFC Brodmann’s areas, and thus areas of the rat brain are demarcated by their 
connections with other brain structures (Rose and Woolsey 1948).  It has been 
argued that the mPFC does not exist in the brains of mammals other than 
primates, (Preuss 1995), but within the neuroscience field, the overwhelming 
amount of literature and research support the hypothesis that  rats possess a 
structure analogous to the primate mPFC (Kolb 1984; Heidbreder and 
Groenewegen 2003; Uylings, Groenewegen et al. 2003; Seamans, Lapish et al. 
2008).                 
As a brain structure that is involved in many global functions, the 
prefrontal cortex (PFC) has long been an area of interest for neuroscientists.  
The PFC has been shown to be critical for higher cognitive processes including 
attention, memory, learning, decision making, and integration.  However, many of 
these processes are interrupted or dysfunctional in pathologies such as 
Alzheimer’s disease, schizophrenia, and drug addiction.   
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Dating back to the mid-twentieth century, studies by Jansen and 
colleagues found that electrical stimulation of the prefrontal cortex in cats 
resulted in “searching” and “attention” responses (Jansen, Andersen et al. 1955).  
Neurons in the prefrontal cortex of monkeys have been shown to have increased 
activation during an attentional task (Suzuki and Azuma 1977)     
The PFC has been shown to be necessary for certain memory processes, 
specifically working memory.  Lesions of the PFC have been demonstrated to 
drastically impair working memory performance in matching-to-sample tasks 
(Winocur 1992; Granon, Vidal et al. 1994), avoidance tasks (Fritts, Asbury et al. 
1998), and visual object discrimination (Ragozzino, Detrick et al. 2002).  
Additionally, antagonism of the PFC glutamatergic system has been shown to 
impair spatial working memory performance (Jentsch, Tran et al. 1997) and 
human fMRI studies suggest that PFC neural activity is responsible for 
maintaining working memory and attention (Rypma and D'Esposito 1999; Hartley 
and Speer 2000; Osaka, Komori et al. 2007; Ikkai and Curtis 2011). Learning 
also involves the PFC, as illustrated in studies with non-human primates (Wise, 
Murray et al. 1996; Asaad, Rainer et al. 1998; Toni and Passingham 1999; 
Pasupathy and Miller 2005).  Specifically, PFC neurons have been shown to be 
most strongly activated when cues are changed during a task (Asaad, Rainer et 
al. 1998), and the PFC has been implicated in learning a visuomotor conditional 
task during PET scans in non-human primates (Toni and Passingham 1999).    
PFC neuronal activity during a trial has also been shown to be dependent on the 
outcome of a previous trial (Histed, Pasupathy et al. 2009).     
Decision making is another example of a PFC integration process, as 
decision making involves evaluating material, predicting outcomes, and then 
making a choice.  In patients with frontal damage, novel choices are difficult 
(Godefroy and Rousseaux 1997), and decisions may be made with only 
immediate outcomes in mind (Bechara, Tranel et al. 2000; Manes, Sahakian et 
al. 2002).  Studies using neuroimaging techniques during decision making tasks 
also implicate the PFC in the decision making process (Paulus, Hozack et al. 
2002; Heekeren, Wartenburger et al. 2003; Rogers, Ramnani et al. 2004).       
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The mPFC has been implicated in the development and maintenance of 
drug addiction.  Lesions of the mPFC have been shown to decrease lever 
pressing for cocaine in rats (Goeders and Smith 1986) as well as eliminate 
cocaine-induced sensitization (Li, Hu et al. 1999), and neuronal firing between 
the mPFC and nucleus accumbens, a structure in the brain involved in drug 
addiction, has been shown to be correlated just prior to the self-administration of 
cocaine (Chang, Janak et al. 2000).  Withdrawl from amphetamines has been 
shown to alter glutamate receptor expression in the mPFC (Lu, Monteggia et al. 
1999), and mPFC glutamate levels have been shown to increase following a 
cocaine challenge dose after a withdrawl period in rats previously treated with 
cocaine (Williams and Steketee 2004).  Together, these data indicate that the 
mPFC at least plays some role in stimulant drug abuse. 
The connections of the PFC are many and of differing modalities.  The 
defining characteristic of the PFC is the projection it receives from the 
mediodorsal nucleus of the thalamus (Leonard 1969; Krettek and Price 1977; 
Divac, Kosmal et al. 1978; Groenewegen 1988).  This projection is glutamatergic 
in nature, and the mPFC sends a reciprocal glutamatergic efferent to the 
mediodorsal nucleus as well (Pirot, Jay et al. 1994).  Glutamatergic afferents 
arise from limbic structures such as the amygdala (Bacon, Headlam et al. 1996; 
McDonald 1996) and the hippocampus (Jay, Thierry et al. 1992), and these 
structures also receive reciprocal glutamatergic efferents from the mPFC.  Within 
the mPFC, glutamatergic recurrent collaterals from pyramidal neurons synapse 
on each other (Pirot, Glowinski et al. 1995).  The mPFC sends glutamatergic 
projections to a variety of brain regions including the nucleus accumbens (NAc) 
(Christie, James et al. 1985), periaqueductal grey matter (Christie, James et al. 
1986), ventral tegmental area (VTA) (Taber, Das et al. 1995; Rossetti, 
Marcangione et al. 1998), and striatum (Karreman and Moghaddam 1996).  A 
second neurotransmitter system, the dopaminergic system, is intimately related 
to the glutamatergic system in the mPFC.  The mPFC receives dopaminergic 
projections from the VTA (Thierry, Blanc et al. 1973; Lindvall, Bjorklund et al. 
1978) that serve to modulate mPFC pyramidal neuronal excitability (Gulledge 
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and Jaffe 2001).  The mPFC can also indirectly influence the NAc (Ungerstedt 
1971; Beckstead, Domesick et al. 1979), hippocampus (Gasbarri, Verney et al. 
1994; Gasbarri, Sulli et al. 1997), and amygdala (Oades and Halliday 1987) via 
dopaminergic projections from the VTA (for a diagram of the mPFC/limbic system 
connections, see Figure 1.1).  The neurotransmitter γ-aminobutyric acid (GABA) 
serves to modulate the mPFC as well.  GABA in the mPFC arises from local 
circuit neurons within the mPFC (Retaux, Julien et al. 1992), as well as from VTA 
projections to the mPFC (Pirot, Godbout et al. 1992; Carr and Sesack 2000).  For 
the purposes of this thesis, the glutamatergic system is the main focus.   
 
Glutamate Regulation  
 
Glutamate, an amino acid, is the major excitatory neurotransmitter of the 
central nervous system. Glutamate was first suggested as a neurotransmitter by 
Hayashi in 1954 (Hayashi 1954), and later confirmed through identification of 
glutamate receptors and specific antagonists (Davies, Evans et al. 1979; Watkins 
and Evans 1981).   
Glutamate signaling involves multiple receptors, transporters, and neurons 
as well as glia (representative synapse is diagrammed in Figure 1.2).  Glutamate 
is synthesized in two ways in the brain.  Glutamate can be created from glucose 
via the Krebs cycle, and glutamate can be synthesized via the glutamate-
glutamine cycle.  Glutamine, a precursor for glutamate synthesis, is readily 
available in extracellular fluid (Hamberger and Nystrom 1984; Fonnum 1993).  
Glutamine is transported into the presynaptic neuron via low affinity transport 
(Erecinska and Silver 1990) and is converted to glutamate via phosphate 
activated glutaminase, an enzyme that is localized to the mitochondria (Laake, 
Takumi et al. 1999).  Intracellular glutamate is then packaged into synaptic 
vesicles by a v-type proton-pump ATPase and a vesicular glutamate transporter 
(VGLUT) (Lewis and Ueda 1998; Bellocchio, Reimer et al. 2000).  Calcium-
triggered exocytosis allows for the delivery of glutamate from the vesicle into the 
synaptic cleft.  It is important to note that glutamate may also enter the synapse 
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through calcium-dependent vesicular release from astrocytes (Montana, Ni et al. 
2004) or through the actions of the cystine-glutamate exchanger, found on glia 
(Baker, Xi et al. 2002).    
Once in the synaptic cleft, glutamate can act on two different types of 
receptors: ionotropic glutamate receptors and metabotropic glutamate receptors.  
Ionotropic glutamate receptors include N-methyl-D-aspartate (NMDA) receptors, 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, and 
kainate receptors (Watkins and Evans 1981) (see Table 1.1 for review).  These 
receptors are all glutamate gated ion channels that conduct Na+ and K+, with 
NMDA receptors also being permeable to Ca2+ (Mayer and Westbrook 1987; 
Ascher and Nowak 1988).  The AMPA and kainate receptors are responsible for 
voltage-independent fast signaling, and are often grouped together as non-
NMDA receptors due to their similar responses to glutamate receptor agonists 
and antagonists (Bettler and Mulle 1995).  These non-NMDA receptors also 
desensitize quickly (Trussell and Fischbach 1989).  NMDA receptors, however, 
are slower to desensitize, and their signaling results in slower changes in 
postsynaptic current (Collingridge, Herron et al. 1988; Hestrin, Nicoll et al. 1990; 
Lester, Clements et al. 1990).  Additionally, NMDA receptors require membrane 
depolarization to remove the Mg2+ block that inhibits ion channel permeability 
(MacDonald and Wojtowicz 1982; Mayer and Westbrook 1985; Flatman, 
Schwindt et al. 1986).   
Metabotropic glutamate receptors (mGluRs) are G-protein coupled 
receptors with seven transmembrane domains.  These receptors signal slower 
due to their protein coupling, and are classified into three groups.  Group I 
mGluRs consist of mGluR1 and mGluR5, group II includes mGluR2 and mGluR3, 
and group III is associated with mGluR4, mGluR6, mGluR7, and mGluR8.  The 
groups differ by their methods of signal transduction and their responses to 
agonists (see Table 1.2 for review).  Together, the ionotropic and metabotropic 
glutamate receptors are essential for glutamate signal transduction. 
Glutamate signaling is tightly regulated within the brain, and glutamate 
uptake is a critically important process for preventing excitotoxicity associated 
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with excess glutamate.  Glutamate is cleared from the synapse by high affinity 
sodium-dependent excitatory amino acid transporters (EAATs).  Five EAATs 
have been identified to date: GLAST (EAAT1), GLT-1 (EAAT2), EAAC (EAAT3), 
EAAT4, and EAAT5.  GLAST and GLT-1, are localized to astrocytes (Storck, 
Schulte et al. 1992) (Pines, Danbolt et al. 1992; Rothstein, Martin et al. 1994; 
Chaudhry, Lehre et al. 1995), while EAAC is localized to neurons (Kanai and 
Hediger 1992; Rothstein, Martin et al. 1994).  EAAT4 is localized to Purkinje cells 
in the cerebellum (Furuta, Rothstein et al. 1997), and EAAT5 is localized to the 
retina (Pow and Barnett 2000).  GLAST and GLT-1 are responsible for glutamate 
uptake into glia.  Once in the glia, glutamate is converted to glutamine by 
glutamine synthase, and the resulting glutamine is released into the extracellular 
space to continue the cycle. 
                     
Methylphenidate and Alterations in Glutamate Neurotransmission  
  
Drug abuse is a problem that has plagued humanity for as long as 
recorded history.  In the United States in 2010, the Substance Abuse and Mental 
Health Services Administration estimated 23 million Americans had used an illicit 
substance within the month prior to data collection (approximately 8.9 percent of 
the population) (2011).  Alarmingly, in 2011, 50% of high school students 
reported using an illicit drug by the time they left high school (Johnston and 
Schulenberg 2012). Illicit drug use has been shown to be associated with risky 
behaviors, including unprotected sex (DeHovitz, Kelly et al. 1994; Diaz, Chu et al. 
1994; Hwang, Ross et al. 2000) and criminal activity (Mumola 1999; Friedman, 
Glassman et al. 2001).  A 2009 study by the National Highway Traffic Safety 
Administration found 18% of fatally injured drivers tested positive for at least one 
substance (2010).    Illicit drug use was also associated with almost one million 
emergency department visits in the U.S. in 2009, and the percentage of 
pharmaceutical misuse or abuse emergency department visits increased 98% 
from 2004 to 2009  (2010).  The costs associated with drug abuse totaled $140 
billion in 1998, with the majority of the costs associated with lost productivity 
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(2001).  Without a better understanding of brain changes associated with drug 
abuse and potential treatments, these costs will continue to climb as our 
population increases.          
One drug with abuse potential that has gained popularity relatively 
recently is methylphenidate (MPH; Ritalin), a stimulant that was first synthesized 
in 1944.  In the brain, the mechanism of action for MPH is similar to other 
stimulants.  MPH binds with high affinity to the dopamine transporter (Ritz, Lamb 
et al. 1987; Heron, Costentin et al. 1994; Pan, Gatley et al. 1994; Wayment, 
Deutsch et al. 1999), and thus inhibits presynaptic reuptake of dopamine, 
allowing for increased concentrations of this neurotransmitter in the extracellular 
space (Hurd and Ungerstedt 1989; Butcher, Liptrot et al. 1991).  This increase in 
extracellular dopamine concentration is responsible for the stimulant effects of 
the drug (Taylor and Snyder 1971; Roberts, Zis et al. 1975).  MPH exerts indirect 
influence over dopamingergic signaling through the vesicular monoamine 
transporter -2 (VMAT-2).  MPH has been shown to increase intracellular 
dopamine uptake into vesicles (Sandoval, Riddle et al. 2002), and redistribute 
VMAT-2 from synaptosomal membranes into the cytoplasm (Volz, Farnsworth et 
al. 2008).  Increases in norepinephrine (NE) release have also been observed 
following MPH administration, as MPH acts on the norepinephrine transporter 
(Wall, Gu et al. 1995; Gatley, Pan et al. 1996).  MPH differs from other 
stimulants, such as amphetamine, in that it has no effect on the serotonergic 
system (Kuczenski and Segal 1997). 
The primary use of MPH is as a medication that is prescribed for the 
treatment of attention-deficit hyperactivity disorder (ADHD) (Sykes, Douglas et al. 
1972; Porges, Walter et al. 1975; Charles, Schain et al. 1981).  Although it 
seems counterintuitive to treat ADHD with a stimulant medication, low-level 
stimulant treatment has been shown to improve cognitive performance in both 
non-ADHD and ADHD-diagnosed children and adolescents (Gabrys 1977; Mohs, 
Tinklenberg et al. 1978; Rapoport, Buchsbaum et al. 1978; Balthazor, Wagner et 
al. 1991; Klein 1993; Gimpel, Collett et al. 2005).  MPH is a schedule II controlled 
substance in the U.S. In 2010, approximately 1.9 million children received MPH 
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prescriptions (Chai, Governale et al. 2012), and it has been estimated that 5-15% 
of children and adolescents in the U.S. are taking MPH (Barbaresi, Katusic et al. 
2002).  MPH is typically taken orally (although transdermal patches are an 
option), and is available in immediate and extended release formulations.  The 
standard treatment dose averages up to 1.0 mg/kg, although this varies among 
individuals (Greenhill, Abikoff et al. 1996), and MPH peak plasma concentrations 
appear roughly two hours after an oral dose is taken (Wargin, Patrick et al. 
1983). MPH is generally accepted as one of the preferred treatments for ADHD 
(Wigal 2009; De Sousa and Kalra 2012).   
However, there is some evidence that ADHD is over diagnosed (Meijer, 
Faber et al. 2009; Bruchmuller, Margraf et al. 2012; Morrow, Garland et al. 2012), 
thus contributing to an increase MPH and other ADHD stimulant medication 
prescriptions (Safer, Zito et al. 1996; Olfson, Gameroff et al. 2003).  This is a 
problem, as misdiagnoses could lead to unnecessary exposure to stimulant –
based pharmacotherapies, especially in children and adolescents.  It has been 
shown that MPH serves as a reinforcer for children diagnosed with ADHD 
(MacDonald Fredericks and Kollins 2005), and animal studies have also 
established the reinforcing effects of MPH (Collins, Weeks et al. 1984; Nielsen, 
Duda et al. 1984).  Rats will self-administer MPH (Botly, Burton et al. 2008; 
Marusich and Bardo 2009; Marusich, Beckmann et al. 2010), and rats exposed to 
MPH during adolescence adapt readily to cocaine self-administration as adults 
(Brandon, Marinelli et al. 2001; Crawford, Baella et al. 2011; Harvey, Sen et al. 
2011).  These experiments help to illustrate the serious abuse potential of MPH 
and highlight the importance of carefully considered ADHD diagnoses.  
Additionally, the physiological side effects of stimulant treatment can be serious.  
MPH is associated with minor increases in blood pressure and heart rate (Stiefel 
and Besag 2010), long term treatment has been shown to stunt physical height in 
children (Zhang, Du et al. 2010) and sleep disturbances are often reported 
(Greenhill, Puig-Antich et al. 1983; Corkum, Panton et al. 2008).   
MPH abuse has been on the increase in college and adolescent 
populations in recent years (DeSantis, Webb et al. 2008; Dupont, Coleman et al. 
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2008; Bogle and Smith 2009; Setlik, Bond et al. 2009).  MPH is abused in the 
college population, often as a “study drug” (Sussman, Pentz et al. 2006; Teter, 
McCabe et al. 2006).  In animal studies, MPH has been shown to increase 
extracellular dopamine in the PFC in rat studies (Bymaster, Katner et al. 2002).  
Additionally, given the increased use of MPH in recent years, both legal and illicit, 
a greater understanding of the effects of MPH on neurochemical signaling is 
warranted.   
Although many neurotransmitter systems have been implicated in the 
development of drug abuse and addiction, the actions of the glutamate system 
warrant further investigation due to the amount of glutamate signaling that occurs 
in the brain.  Previous studies have linked alterations in glutamate 
neurotransmission with abuse of substances including cocaine (Pulvirenti, 
Swerdlow et al. 1989; Pulvirenti, Swerdlow et al. 1991; Witkin 1993), 
amphetamine (Pulvirenti, Swerdlow et al. 1989; Kelley and Throne 1992), 
methamphetamine (Hara, Akaike et al. 1987; Earle and Davies 1991; Witkin 
1993), heroin (Pulvirenti, Swerdlow et al. 1991; Xi and Stein 2002), phencyclidine 
(Idriss and Albuquerque 1985; Loo, Braunwalder et al. 1987), and alcohol (Freed 
and Michaelis 1978; Michaelis, Michaelis et al. 1980; Ledig, M'Paria et al. 1982).   
In light of the fact that glutamate is responsible for some of the signaling within 
the reward circuitry in the brain, glutamate likely plays a role in the development 
and maintenance of addiction.  As previously described, the mPFC maintains 
connections with the mesolimbic dopamine system, which is implicated in the 
reward circuitry of addiction. 
Despite the amount of literature in the area of drug addiction research, 
MPH’s effects on the glutamate system are not yet well understood.  However, 
other stimulants have been reported to increase glutamate levels in the PFC 
(Reid, Hsu et al. 1997).  In the studies detailed in this dissertation, the effects of 
MPH on the glutamate system in the mPFC were explored using an advanced 
neurochemical monitoring technique, the microelectrode array.    
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Microelectrode Array Measurements of Glutamate 
Neurotransmission 
The ability to accurately measure in vivo levels of neurotransmitters has 
long been a topic of interest in the field of neuroscience.   Microdialysis has been 
the preferred method for measuring neurochemistry since the early 1980s 
(Zetterstrom, Sharp et al. 1983; Benveniste and Huttemeier 1990).  Until recently, 
microdialysis was unchallenged as the gold standard technique for measuring in 
vivo levels of neurotransmitters in the mammalian central nervous system, and 
the majority of what is known about mPFC glutamate and levels comes from 
microdialysis studies.  However, microdialysis is limited in two critical areas 1) by 
its temporal resolution (minutes) (Nandi and Lunte, 2009) and 2) by its spatial 
resolution (millimeters) (Clapp-Lilly et al., 1999). Furthermore it has been shown 
to cause extensive brain damage (millimeters) around the probe (Clapp-Lilly et 
al., 1999; Georgieva et al., 1993; Grabb et al., 1998).   
Our group has worked extensively on a microelectrode array (MEA) 
technology that allows for measurements of neurotransmitter synaptic spillover at 
rates of 1-4 Hz.  With platinum recording sites having a small footprint (15 x 333 
µm) and measuring neurotransmitters in the nanomolar range, the MEAs allow 
for the characterization of specific brain sub-regions, such as those in the 
prefrontal cortex (Bruno et al., 2006; Burmeister et al., 2008; Day et al., 2006; 
Nickell et al., 2005; Stephens et al., 2009).  Additionally, the multiple Pt recording 
sites of the MEA allow for a self-referencing technique that subtracts background 
current and provides in vivo measurements of glutamate concentration. MEAs 
can readily be used in anesthetized or awake experiments, allowing for 
measurements of neurochemistry in multiple brain regions, or while 
simultaneously monitoring animal behavior.  
The advanced spatial and temporal resolution of MEA technology has 
allowed us to characterize mPFC sub-regional glutamate neurotransmission to a 
degree never before reported.  Additionally, we have been able to use this 
technique to examine the effects of MPH on the glutamate system, observe 
dynamic changes in phasic glutamate signaling, and measure tonic glutamate 
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levels during awake freely-moving animal experiments.  The information gained 
from these experiments will help the neuroscience field to better understand the 
role of glutamate in the mPFC in drug addiction.   
    
Portions of this chapter have been previously published in the manuscript: 
Mattinson, C.E., Burmeister, J.J., Quintero, J., Pomerleau, F., Huettl, P., 
Gerhardt, G.A. 2011. Tonic and phasic release of glutamate and 
acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex 
using enzyme based microelectrode arrays. J Neurosci Methods.  202 (2): 
199-208. 
Permission was obtained from Elsevier for use. 
Copyright © Catherine Elizabeth Mattinson 2012 
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the NMDA receptor or AMPA/KA receptors.  Glutamate can also be taken up into 
the postsynaptic neuron by the excitatory amino acid transporter EAAC.  On the 
glia, glutamate can be cleared from the synapse by the excitatory amino acid 
transmitters GLT-1 and GLAST.  Glia also possess mGluRs, and glutamate can 
be returned to the synapse via the actions of the glutamate/cysteine exchanger.  
Within the glia, glutamate is converted to glutamine via glutamine synthetase.  
Glutamine diffuses in the extracellular space, and is taken up by presynaptic 
neurons for further use. Figure adapted from (Schoepp 2001). 
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Table 1.1: Characteristics of Ionotropic Glutamate Receptors 
 Ionotropic Glutamate Receptors 
 NMDA AMPA Kainate 
Receptor 
Selective 
Agonists 
NMDA AMPA Kainic acid 
Other Agonists Ibotenate 
Quinolinate 
L-aspartate 
Homocysteate 
Quisqualic acid Domoic acid 
Receptor 
Selective 
Antagonists 
D-AP5 
D-AP7 
CGS-19755 
CGP-37849 
CGP-40116 
CPP 
CNQX 
DNQX 
CNQX 
DNQX 
Other 
Antagonists 
CGS 19755 
 
NBQX 
GYK1 52466 
 
Channel 
Blockers 
MK-801 
Phencyclidine 
  
Ionotropic glutamate receptors are divided into three types, based on their 
interactions with specific small signaling molecules.  The discussion of agonist 
and antagonists is made more complicated by the glutamate and glycine binding 
sites on NMDA receptors, thus only the glutamate binding sites are described in 
this table.    Abbreviations: NMDA, N-methyl-D-aspartate; D-AP5, (R)-2-amino-5-
phosphonopentanoate; D-AP7, amino-7 phosphonoheptanoic acid; CGS-19755, 
(±)-cis-4-phosphonomethyl-2-piperidine carboxylic acid; CPP, 3-(2-
carboxypiperazin-4-yl)-propyl-1-phosphonic acid; MK-801, dizocilpine; AMPA, α-
amino-3-hydroxy-5-methyl-4-isoazolepropionic acid; CNQX, 6-cyano-7-
nitroquinoxaline-2,3-dione; DNQX, 6,7-dinitro-quinoxaline-2,3-dione; NBQX, 2,3-
dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline; GYK1 52466, 1-(4-
aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine.  Adapted 
from Cooper et al., 2003.    
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Table 1.2: Characteristics of Metabotropic Glutamate Receptors 
 Receptor G Protein 
and 
Function 
Location  Agonists Antagonists 
Group 
I 
mGlu1 Gq; 
increased 
PLC 
Postsynaptic 
neurons 
3,5-DHPG 
quisqualate 
CPCCOEt 
LY367385 
EMQMCM 
JNJ16259685
YM298198 
mGlu5 Gq; 
increased 
PLC 
Postsynaptic 
neurons, glia 
MPEP 
MTEP 
Fenobam 
Group 
II 
mGlu2 Gi, Go; 
decreased 
AC 
Pre- and 
postsynaptic 
neurons 
DCG-IV 
APDC 
LY379268 
LY354740 
LY404039 
LY389795 
EGLU 
LY341495 
LY307452 
mGlu3 Gi, Go; 
decreased 
AC 
Postsynaptic 
neurons, glia 
Group 
III 
mGlu4 Gi, Go; 
decreased 
AC 
Pre- and 
postsynaptic 
neurons 
L-AP4 
L-SOP 
PPG 
 
3,4-DCPG 
(mGlu8) 
CPPG 
MAP4 
 
 mGlu6 Gi, Go; 
decreased 
AC 
Retinal tissue 
dendrites 
mGlu7 Gi, Go; 
decreased 
AC 
Pre- and 
postsynaptic 
neurons 
mGlu8 Gi, Go; 
decreased 
AC 
Pre- and 
postsynaptic 
neurons 
Metabotropic glutamate receptors consist of eight different receptors that are 
divided into three groups based on their characteristics.  Abbreviations: PLC, 
phospholipase C; AC, adenyl cyclase;  3,5-DHPG, 3,5-dihydroxyphenylglycine; 
DCG-IV, (2S,2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine; APDC, 2R,4R-4-
aminopyrrolidine-2,4-dicarboxylic acid; L-AP4, (S)-2-amino-4-phosphonobutanoic 
acid; L-SOP, S-serine-O-phosphate PPG, (RS)-4-phosphonophenylglycine; 4,3-
DCPG, CPCCOEt, 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid 
ethyl ester; EMQMCM, (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-
methanone methane sulfonate; MPEP, 2-methyl-6-(phenylethynyl)pyridine; 
MTEP, 3-[2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine; EGLU, (S)-α-ethylglutamic 
acid; CPPG, (RS)-α-cyclopropyl-4-phosphonophenylglycine; MAP4, (S)-α-
methyl-2-amino-4-phosphonobutanoic acid.  Adapted from Schoepp, 2001. 
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Thesis Outline 
There exists a paucity of information in our current understanding of tonic 
and phasic glutamate signaling in the mPFC, and thus not much is known about 
how stimulant drug use affects glutamatergic signaling in this brain region.  The 
studies detailed in this dissertation sought to further explore and characterize 
glutamate neurotransmission, and explore the effects of MPH on glutamate 
signaling in the mPFC.  In Chapter Three, we investigated glutamate and 
acetylcholine (ACh) dynamics in the cingulate, prelimbic, and infralimbic sub-
regions of the mPFC.  The glutamatergic and acetylcholinergic 
neurotransmission of the individual sub-regions of the mPFC has not been well 
characterized in the literature, as microdialysis probe size is prohibitive for 
measuring these distinct brain regions.  Our results revealed uniform resting 
levels for each neurotransmitter among the three sub-regions.  KCl-evoked 
release of glutamate and ACh resulted in similar peak amplitude concentrations 
within each neurotransmitter among the sub-regions.  However, comparison of 
peak amplitudes and T80 values between glutamate and ACh revealed significant 
differences.  These data suggest an unexpected uniformity of both glutamate and 
ACh signaling in the mPFC.  
Chapter Four chronicles the characterization of glutamate signaling in the 
infralimbic mPFC in the awake freely moving animal.  We sought to identify and 
measure rapid and dynamic changes in glutamate signaling termed glutamate 
‘transients’.  The infralimbic sub-region was identified as an area of interest due 
to its multiple roles in higher cognitive processes, as well as the potential it has 
for circadian influences.  24 hours recordings showed significant effects in 
glutamate resting levels, transient glutamate events, and peak amplitude 
concentrations.  Correlations were found between glutamate transients and 
glutamate concentrations, as well as glutamate concentrations and locomotor 
activity.  These data confirm the presence of transients in the infralimbic mPFC, 
and highlight relationships between glutamate signaling parameters during light 
and dark cycle phases.  
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The effects of MPH on glutamate signaling were explored in Chapter Five.  
A depth profile analysis was performed through three sub-regions of the mPFC 
following chronic treatment with MPH to identify any alterations in glutamate 
signaling.  Rats chronically treated with MPH showed increased locomotor 
activity during the treatment period as compared to saline controls.  Data did not 
reveal any significant differences in resting levels of glutamate among sub-
regions or between treatment groups.  Chronically MPH-treated animals trended 
towards higher glutamate concentration than their saline counterparts.  KCl-
evoked glutamate release did not differ in peak amplitude, T80 values, or uptake 
rates among sub-regions or between groups, but T80 values in the prelimbic and 
infralimbic sub-regions of chronically MPH-treated rats tended to be increased as 
compared to chronically saline-treated rats.  These data indicate that MPH does 
produce significant locomotor effects, and that MPH treatment did not 
significantly alter glutamate neurotransmission.  However, the effects of 
anesthetic are a possible confound, and further studies need to be performed in 
awake-freely moving animals. 
Chapter Six examines the effects of MPH treatment on infralimbic 
glutamate neurotransmission in the awake freely-moving rat.  In addition to 
avoiding the possible confounds of urethane anesthesia, unanesthetized 
experiments allow for the simultaneous measurement of behavior and glutamate 
signaling.  Significant effects were found in locomotor activity from the chronic 
treatment period, as well as during saline, MPH and cocaine challenge doses.  
Significant effects were also seen in glutamate resting levels during these 
challenge doses.  These data support behavioral sensitization associated with 
MPH administration, and indicate that infralimbic mPFC glutamate resting levels 
may play a role in the reinforcing effects of chronic MPH treatment. 
Chapter Seven serves to provide a summation of the results and 
interpretations of this body of work.  The findings from these experiments are 
discussed and future experiments are suggested to continue to expand upon this 
area of research.        
Copyright © Catherine Elizabeth Mattinson 2012 
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Chapter Two: Materials and Methods 
 
Chemicals 
Reagents were purchased from Sigma-Aldrich (St. Louis, MI), except 
where noted.   
 
Animals  
 
Male Fischer 344 rats or male Sprague-Dawley rats were used for all 
experiments (Harlan, Indianapolis, IN).  The animals were given access to food 
and water ad libitum, and were maintained on a 12 h light: 12 h dark cycle (lights 
on at 06:00 h).  Animals were individually housed, and were monitored by the 
Department of Laboratory Animal Resources at the University of Kentucky.  All 
protocols were reviewed and approved by the Institutional Animal Care and Use 
Committee.   
 
Amperometry 
Recordings were generated by applying a constant potential of +0.7 V vs. 
a Ag/AgCl reference electrode to a microelectrode array.  The potential allowed 
for electroactive substances, such as the reporter molecule H2O2, to be oxidized 
at the platinum recording sites on the microelectrode array.  The resulting current 
was digitized by a Fast Analytical Sensing Technology-16 mkII potentiostat 
(FAST-16 mkII; Quanteon LLC, Nicholasville, KY) into a signal that could be 
analyzed.    
 
Microelectrode Array Configuration and Preparation 
 
Microelectrode Array Fabrication 
Microelectrode arrays were manufactured in conjunction with Thin Film 
Technologies, Inc. (Buellton, CA), and a detailed description of the process is 
available in previously published articles (Burmeister, Moxon et al. 2000; 
Burmeister and Gerhardt 2001).  Briefly, a photomask was used to pattern 
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electrodes onto ceramic wafers (Coors Ceramics Co., Golden, CO).  Titanium 
and platinum were sputter-coated onto the ceramic, and lift off revealed the 
recording sites and connecting lines.  Ceramic electrodes were cut from the 
wafers and bonded to printed circuit boards (Hybrid Circuits, Inc., Sunnyvale, 
CA).  Microelectrode surfaces, except for the recording sites, were insulated with 
a polyimide coating to minimize cross-talk between the recording sites.       
 
Microelectrode Array Site Configuration 
The S-2 microelectrode pad configuration was used for all experiments.  
The S-2 microelectrode array consists of four platinum recording sites, each 
measuring 15 x 333 µm.  The sites are arranged two pairs, with 30 µm 
separating the sites within a pair, and 100 µm separating the two pairs vertically.  
The bottom pair of sites begins 100 µm from the tapered end of the ceramic tip.  
This configuration is pictured in Figure 2.1.   
 
Modifications for Awake Freely-Moving Recordings 
 For unanesthetized experiments, the microelectrode array circuit board 
was modified to reduce the size of the implant.  The process of fabricating this 
type of microelectrode array has been previously described (Rutherford, 
Pomerleau et al. 2007; Hascup, Hascup et al. 2008).  Briefly, 30 gauge varnished 
copper wire (Radioshack, Ft. Worth, TX) was cut into one inch long pieces.  The 
coating was removed approximately 1/8” in from either end.  One end of the wire 
was soldered into a small gold-plated socket (Ginder Scientific, Nepean, ON).  
The other end of the wire was soldered to the “stub” type circuit board of the 
microelectrode array.  After all four channels were soldered, the gold-plated 
sockets were inserted into a black nine pin ABS plug (Ginder Scientific, Nepean, 
ON).  A miniaturized Ag/AgCl reference electrode was also inserted into the plug.  
The wires were arranged so that they did not touch each other or solder.  Loctite 
Quickset Epoxy (Henkel Corp., Rocky Hill, CT) was used to cover and secure the 
wires and electrode to the plug.  The epoxy was allowed to cure for a minimum of 
24 hours before microelectrode array implantation.     
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Microelectrode Array Coatings 
 Microelectrode arrays were prescreened through a cleaning and 
preliminary testing process to minimize inherent platinum recording site 
differences.  Enzyme coatings (Figure 2.1) were used to make the 
microelectrode arrays selective for and sensitive to glutamate.  This process has 
been described previously (Burmeister and Gerhardt 2001; Burmeister, 
Pomerleau et al. 2002; Day, Pomerleau et al. 2006).  Glutamate detecting 
microelectrode arrays were coated with a solution of 0.1 units/µL glutamate 
oxidase, 1% bovine serum albumin (BSA), and 0.125% glutaraldehyde on one 
pair of platinum recording sites, while the second pair of recording sites was 
coated with only the BSA/glutaraldehyde coating matrix solution Three coats of 
each solution were applied to their respective sites using 10 µl Hamilton syringes 
(Hamilton Co., Reno, NV), with one minute of curing time allowed between each 
coat.  Microelectrode arrays cured at room temperature for a minimum of 48 
hours before use.   
 
Exclusion Layers 
An exclusion layer was applied to the microelectrode surface to minimize 
potential electroactive interferents, such as ascorbic acid, from coming into 
contact with the platinum recording sites.  Different exclusion layers were used 
for anesthetized versus awake freely-moving recordings.  In the anesthetized 
preparation, a size exclusion layer of m-Phenylenediamine (mPD; 5 mM in 0.5 M 
phosphate-buffered saline; Acros Organics, Geel, Belgium) was electrodeposited 
on to the platinum recording sites prior to calibration.  mPD excludes interferents 
based on the size of the molecule, thus excluding ascorbic acid and allowing 
H2O2 to reach the platinum recording sites.  In preparation for awake freely 
moving experiments, Nafion®, a poly-sulfonated Teflon® derivative, was coated 
onto microelectrode arrays by swirling the ceramic tip of the microelectrode in 
Nafion® and then baking the microelectrodes for four minutes at 200˚C.  Nafion® 
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excludes interferents based on the charge of the molecule, and is generally 
thought to be more stable for chronic in vivo measurements.         
 
Microelectrode Array Calibrations 
All microelectrode arrays were calibrated in vitro before implantation.  
Microelectrode arrays with a Nafion® exclusion layer were soaked in phosphate 
buffered saline (PBS) solution (0.05 M, pH = 7.4) for a minimum of 30 minutes 
prior to calibration to activate the exclusion layer.  PBS (40 mL) was added to a 
50 mL beaker, and placed in a water bath maintained at 37˚C by a recirculating 
pump (Gaymar Industries, Inc., Orchard Park, NY).  A miniature stir bar was 
added to the beaker, and the solution was stirred by a battery-operated, portable 
magnetic stir plate (Barnant Co., Barrington, IL).  A glass Ag/AgCl reference 
electrode (Bioanalytical Systems, West Lafayette, IN) and approximately half of 
the ceramic tip of the MEA were lowered into the PBS.  The calibration was 
performed using FAST system software.  During the calibration, ascorbic acid (20 
mM; 500 µL) was added as an interferent, and three serial additions of glutamate 
(20 mM; 40 µL) were added to establish the slope of the signal in response to 
glutamate (Figure 2.2).  Dopamine (2 mM; 40 µL) and H2O2 (8.8 mM; 40 µL) 
were also used as a test substance and a positive control, respectively.     
Parameters of interest included slope, limit of detection (LOD), linearity of the 
response to the glutamate additions, and selectivity for glutamate over other 
substances. 
 
Reference Electrode Preparation 
For in vivo experiments, a miniature Ag/AgCl reference electrode was 
created using Teflon®-coated silver wire (A-M Systems, Inc., Sequim, 
Washington, 0.008” bare, 0.011” coated).  The wire was stripped approximately 
1/8” from each of the ends.  For anesthetized preparations, one end of the wire 
was soldered into a gold pin amphenol (Mill-Max Mfg. Corp., Oyster Bay, NY).  
For awake freely moving preparations, one end of the wire was soldered into a 
gold-plated socket.  The other end was placed in a 1 M HCl solution that was 
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saturated with NaCl.  A platinum wire that served as the cathode was also 
submerged in the plating bath.  A nine-volt power supply (Elenco Inc., Wheeling, 
IL) was used to anodize the silver wire for 15 minutes.  After plating, the Ag/AgCl 
reference electrode was stored in an amber bottle containing 3 M NaCl until use.     
 
Application of Intracranial Solutions 
For anesthetized experiments, a glass micropipette was affixed to the 
microelectrode array to allow for pharmacological manipulation in vivo. A glass 
micropipette (A-M Systems, Inc.; 1 mm o.d., 0.58 i.d.,) was pulled using a vertical 
pipette puller (David Kopf Instruments, Tujunga, CA).  The micropipette was 
bumped to an inner diameter of approximately 10 µm.  Sticky wax (Kerr Corp., 
Orange, CA) was used to adhere the micropipette to the microelectrode array, 
with the micropipette tip centered between the four platinum recording sites and 
approximately 75 µm from the surface of the microelectrode array. 
 
Microelectrode Array Implantation Surgery and Recordings 
 
Anesthetized Surgery Procedures 
On the day of surgery, rats were anesthetized with urethane (25%; 1.25 
g/kg).  Once the toe pinch response was absent, rats were secured in a 
stereotaxic frame (David Kopf Instruments).  The rats were shaved at the surgery 
site, and then disinfected using ethanol (70%).  A craniotomy was performed, 
and stereotaxic coordinates (Paxinos 2009) were used to determine the location 
of the mPFC (from bregma, AP: +3.2 mm; ML: ±0.8 mm; DV: -1.5 to -5 mm).  A 
placement hole for the microelectrode array was drilled into the skull, and in the 
contralateral hemisphere, a hole was drilled for reference electrode placement.  
The micropipette was loaded with the solution of interest, and connected to a 
Picospritzer III (Parker Hannifin, Cleveland, OH).  The microelectrode array 
assembly was then stereotaxically placed and lowered to each depth using a 
microdrive.  The rat brain and surrounding tissues were kept moist during the 
experiment using cotton pellets (Richmond Dental, Charlotte, NC). 
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Anesthetized Recordings 
 Once the microelectrode array was lowered to its first depth, the FAST 
system software started recording.  The recordings were allowed a minimum of 
one hour to reach baseline levels before pharmacological manipulations began.  
Each time the microelectrode array was lowered to a new depth, a minimum of 
ten minutes was given for baseline levels to reestablish.   After baseline was 
achieved, multiple ejections of the substance of interest were performed with a 
minimum of one minute between each ejection.  The rate, pressure, and volume 
of the ejections were controlled by the Picospritzer III.  The volume of the 
ejections was confirmed using a stereomicroscope that was fitted with a 
calibrated reticule.                
 
Awake Freely Moving Surgery Procedures 
 Prior to surgery, rats were given an injection of carprofen (Rimadyl®, 
Pfizer, Inc., New York City, NY; 10 mg/kg, s.c.).  Isoflurane (Isothesia, Butler 
Schein, Dublin, OH) was used as the anesthetic for all survival surgeries.  Initial 
anesthesia was induced with 5% isoflurane, and once the rat was secured in the 
stereotaxic frame, the isoflurane level was reduced to 2.5%.  Artificial tears 
(Rugby Laboratories, Inc., Duluth, GA) were applied to the rat’s eyes.  The rat’s 
head was shaved, and three applications each of Providone scrub (The Butler 
Co., Columbus, OH) and ethanol (70%) were used to disinfect the surgery site.  
A craniotomy was performed, and five holes were drilled: one for the 
microelectrode array placement, one for the reference electrode placement, and 
three for anchoring skull screws.  After the skull screws were placed in the skull, 
dura was reflected and the microelectrode array was stereotaxically placed in the 
IL mPFC (from bregma, AP: +3.2; ML: ±0.8; DV: -4.5 mm), with the reference 
electrode positioned in its placement hole.  Multiple applications of dental cement 
(Ortho Jet Powder and Jet Acrylic Liquid, Lang Dental Manufacturing Co., Inc., 
Wheeling, IL) were used to secure the microelectrode array assembly to the rat’s 
skull.  The animals were monitored in their home cages following surgery until 
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normal locomotion was observed.  Animals received daily injections of carprofen 
for the three days following surgery. 
 
Awake Freely-Moving Recordings          
 Recordings began a minimum of 72 hours after surgery.  The animal was 
hooked up to the connector which consisted of a miniaturized potentiostat 
attached to a tether (Figure 2.3), which in turn was hooked up to a swivel in the 
recording chamber to allow the animal to move freely within the chamber.  Within 
the recording chamber, a Digiscan Animal Monitoring device (Omnitech, Inc., 
Sioux Falls, SD) measured animal movement during the experiments.  After hook 
up, rats were allowed at least one hour to baseline before data was collected.  
Rats were monitored during experiments to ensure that they did not interfere with 
their tethers.  After the experiment, rats were returned to their home cages.   
 
Data Collection 
 During each experiment, parameters including resting levels of glutamate, 
peak amplitude of the glutamate signal (either evoked or spontaneous), T80 (time 
for 80% of the signal to decay back to baseline), and uptake rate were collected 
and analyzed (Figure 2.4) using a custom Matlab®-based (The Mathworks, Inc., 
Natick, MAJ) analysis package.  Statistics were performed using GraphPad 
Prism® 5 (GraphPad Software, La Jolla, CA).    
 
Histology 
At the end of an experiment, the animal was euthanized under heavy 
anesthesia.  The brain was removed and flash frozen with dry ice.  Brains were 
stored at -80˚C until sliced on a cryostat into 40 µm coronal sections.  After being 
mounted on slides, brains were stained with cresyl violet and microelectrode 
placement in the mPFC was visually confirmed.  If the placement could not be 
confirmed, the animal was excluded from the study.      
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Portions of these methods have been previously published in the manuscript: 
Mattinson, C.E., Burmeister, J.J., Quintero, J., Pomerleau, F., Huettl, P., 
Gerhardt, G.A. 2011. Tonic and phasic release of glutamate and 
acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex 
using enzyme based microelectrode arrays. J Neurosci Methods.  202 (2): 
199-208. 
Permission was obtained from Elsevier for use. 
Copyright © Catherine Elizabeth Mattinson 2012 
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Chapter Two: Figures 
 
 
 
Figure 2.1 Microelectrode Array Glutamate Coating Schematic 
The ceramic tip of the S-2 configuration of the microelectrode array features four 
platinum recording sites arranged in two pairs (center).  On the bottom pair of 
sites, a glutamate oxidase (GluOx) coating is applied (left).  When glutamate 
(Glu) comes into contact with the glutamate oxidase, it is oxidized into H2O2 and 
α-ketoglutarate.  The H2O2 is free to diffuse, and when it comes into contact with 
a platinum recording site (Pt) while a potential of 0.7 V vs. Ag/AgCl reference is 
applied, the H2O2 is oxidized and donates 2 electrons to the site.  An exclusion 
layer of meta-phenylenediamine (mPD) is electroplated onto the microelectrode 
array surface, and serves to insulate the sites from potentially electroactive 
substances such as DOPAC and ascorbic acid (AA).  The top pair of sites (right) 
is coated with the coating matrix lacking enzyme.  Thus, it cannot generate a 
glutamate signal.  The signal from the top pair of sites is subtracted from the 
bottom pair of sites to isolate a self-referenced glutamate signal.     
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Figure 2.2  In Vitro Calibration of a Glutamate Selective Microelectrode Array  
An in vitro calibration is performed before all experiments.  Channels 1 and 2 are 
coated with glutamate oxidase, and channels 3 and 4 are only coated with the 
coating matrix.  Phosphate buffered saline (PBS, 0.05M, 40 mL) is heated to 
37˚C in a water bath.  A microelectrode array and a reference electrode are both 
submerged in the PBS, and the recording software is started.  After baseline has 
been established, 250 µM ascorbic acid (AA; final beaker concentration) is added 
to ensure that the exclusion layer is intact.  Next, three serial additions of 
glutamate (Glu) are pipetted into the beaker, totaling a concentration of 60 µM.  
These stepwise increases in glutamate are used to calculate the slope of the 
electrode.  An addition of dopamine (DA; final beaker concentration of 2 µM) also 
serves to ensure that the exclusion layer is working.  Finally, an addition of H2O2 
(final beaker concentration of 8.8 µM) is made as a positive control, to ensure 
that all recording sites can measure the reporter molecule. 
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Figure 2.4 Data Parameters of Interest 
During the experiment, resting levels of glutamate are calculated by subtracting 
the signal from the sentinel sites from the signal from the glutamate recording 
sites.  Peak amplitude is the peak magnitude of the signal, either from an evoked 
release (75-100 nL of KCl (70 mM, pH 7.4); indicated by black arrow) or from a 
spontaneous release.  The T80 value is the time it takes for 80% of the signal to 
decay back to baseline.  The uptake rate is the product of the peak amplitude 
and the k-1 value.  The k-1 value represents the best fit line of the first order decay 
of the signal.   
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Chapter Three: Tonic and Phasic Release of Glutamate and 
Acetylcholine in the Rat Prefrontal Cortex Sub-Regions using 
Enzyme-Based Microelectrode Arrays 
 
Introduction 
The mPFC is an area of the brain that is critically involved in higher 
cognitive processes such as learning, memory, and attention, and within the 
mPFC exist multiple sub-regions, including the cingulate, prelimbic, and 
infralimbic mPFC. Glutamate and ACh in combination with monoamine 
neurotransmitters (Berger et al., 1976; Brown et al., 1979; de Brabander et al., 
1993; Gratton et al., 1989; Perry et al., 2011; Thierry et al., 1983) are essential 
for prefrontal cortical functioning.    The mPFC receives glutamatergic inputs from 
the thalamus (Gigg et al., 1992; Leonard, 1969; Pirot et al., 1994), basal 
forebrain (Henny and Jones, 2008), hippocampus (Gigg et al., 1994; Jay et al., 
1992), and amygdala (McDonald, 1996).  This brain area also receives ACh input 
from the basal forebrain as part of the basal forebrain cortical cholinergic system 
(Mesulam et al., 1983).  The loss or antagonism of these specific glutamatergic 
and acetylcholinergic afferents has been shown to result in deficits in spatial 
working memory (Bailey and Mair, 2005; Romanides et al., 1999), passive 
avoidance tasks (Torres et al., 1994), and attention (McGaughy et al., 1996), 
highlighting the importance of these neurotransmitter systems in daily cognitive 
functioning.  Dysregulation of the glutamatergic and/or acetylcholinergic circuitry 
in the mPFC has been implicated in disorders such as schizophrenia (Bauer et 
al., 2008; Benes et al., 1992; Crook et al., 2001; Olbrich et al., 2008; Oni-Orisan 
et al., 2008; Sarter et al., 2005; Tsai et al., 1995; Woo et al., 2008; Zmarowski et 
al., 2009), Alzheimer’s disease (Burbaeva et al., 2005; Francis et al., 1999; 
Kashani et al., 2008; Perry et al., 2011; Trabace et al., 2007), and drug addiction 
(Arnold et al., 2003; Lu et al., 1999; McFarland et al., 2003; Sofuoglu and 
Mooney, 2009; Williams and Steketee, 2004).  The overlap and possible 
interactions of these two neurotransmitter systems underscores the importance 
of understanding both the tonic and phasic aspects of glutamate and ACh 
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neurochemical signaling in the mPFC and could lead to a better understanding of 
alterations associated with neuropathologies.      
   
In this chapter, we report experiments that used our MEA technology to 
gain insight into potential sub-regional differences in tonic and phasic release of 
glutamate and ACh in the rat mPFC.  We first measured resting neurotransmitter 
levels within the cingulate, prelimbic, and infralimbic mPFC. Secondly, we 
examined the dynamics of KCl-evoked release of glutamate and ACh in the 
cingulate, prelimbic and infralimbic to investigate additional transient or phasic 
release of these neurotransmitters.  These experiments provide new information 
regarding the regional signaling properties of glutamate and ACh in different sub-
regions of the mPFC, an area of the brain that is implicated in many 
neuropathologies. 
 
Materials and Methods 
 
Animals 
Male Fischer 344 rats (Harlan, Indianapolis, IN), aged 3 – 6 months, were 
used for all experiments (n = 17).  For care, see Animals. 
 
Microelectrode Array Preparation 
Ceramic based conformal MEAs were made sensitive to and selective for 
glutamate or ACh detection using enzyme layers coated onto the surface of 
platinum (Pt) recording sites (Day, Pomerleau et al. 2006; Burmeister, Pomerleau 
et al. 2008).  Glutamate coatings are detailed Microelectrode Configuration and 
Preparation – Microelectrode Coatings.  MEAs configured for ACh detection 
(Figure 3.1) required a dual enzyme coating scheme to produce the H2O2 
reporter molecule, as ACh is also non-electroactive.  Acetylcholinesterase was 
used to hydrolyze ACh into acetate and choline, and then choline was 
catalytically oxidized by choline oxidase to produce H2O2 (Bruno et al., 2006).  
MEAs were coated with a solution of 0.2 units/µl choline oxidase, 0.9% BSA and 
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0.11% glutaraldehyde on all four sites and allowed to cure at 4˚C for a minimum 
of 48 hours.  MEAs were then coated with 0.83 units/µl human recombinant 
acetylcholinesterase, 0.83% BSA, and 0.10% glutaraldehyde on one pair of sites, 
and the BSA/glutaraldehyde solution on the other pair of sites to ensure 
comparable coating thickness between the pairs of sites and to allow for self-
referencing (Burmeister et al., 2008).  In order to enhance selectivity a size 
exclusion layer of mPD was electrodeposited on to the Pt recording sites prior to 
calibration.  Each of the MEA sites were tested to determine selectivity vs. 
dopamine during an in vitro calibration to ensure that the mPD electrodeposited 
onto sites was uniform.  The signal from the choline oxidase-coated sites was 
subtracted from the combined acetylcholinesterase/choline oxidase sites to 
determine the self-referenced ACh signal.  
 All recordings were performed at a final output frequency of 1 Hz.  Before 
each experiment, MEAs were calibrated in vitro using stepwise additions to 
increase concentrations of glutamate or ACh, as well as, electroactive 
interferents as previously described (Burmeister and Gerhardt, 2001; Burmeister 
et al., 2002).  Sensitivity, linearity, limit of detection, and selectivity over 
electroactive interferents were calculated for all MEAs using the in vitro 
calibration data prior to experimentation. MEAs used in glutamate experiments 
had an average slope of -4.2 ± 2.0 pA/µM, an average limit of detection of 0.99 ± 
0.9 µM, a linearity R2> 0.99, and an average selectivity of 57:1 ± 37.  In ACh 
experiments, MEAs averaged a slope of -5.8 ± 2.6 pA/µM, a limit of detection of 
0.30 ± 0.44 µM, a linearity R2> 0.99, and a selectivity of 420:1 ± 720.     
 
In Vivo Recordings 
Animals were anesthetized for in vivo recordings, and surgery was 
performed (Microelectrode Array Implantation Surgery and Recordings – 
Anesthetized Surgery Procedures; Anesthetized Recordings).  The micropipette 
attached to the MEA was filled with an isotonic KCl solution (70 mM KCl, 79 mM 
NaCl, 2.5 mM CaCl2 • 2H2O; pH = 7.4) and connected to a Picospritzer III (Parker 
Hannifin Corp, NJ) to allow for local applications of KCl into the extracellular 
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space . The MEA/micropipette assembly was lowered into the mPFC (AP: +3.2 
mm; ML: ±0.8 mm; DV: -1.5 to -5 mm; from bregma (Paxinos and Watson, 2009) 
using a Narishige MO-10 microdrive.  The MEA assembly was lowered in 0.5 mm 
increments and recordings were taken at each depth to record glutamate or ACh 
levels along the dorsal-ventral axis of the mPFC. Once lowered into place, basal 
levels were established over ten minute recording durations, and then KCl 
solution was ejected (75-100 nl) to evoke glutamate or ACh signals  
 
Histology 
At the end of the experiment, animals were euthanized and histology was 
performed to confirm MEA placement (Histology; Figure 3.3). Only data collected 
from confirmed electrode placements in the different sub-regions of the mPFC 
were included in the final data analysis; data from two animals were excluded in 
these studies.             
 
Data Analysis and Statistics 
Collected data were processed using a custom Matlab®-based analysis 
package (Data Collection).  Data parameters analyzed were resting (tonic 
release) neurotransmitter levels (average of the ten data points prior to the first 
ejection at each depth) and data from KCl-evoked release (phasic release) of 
glutamate or ACh that included: peak amplitude, T80 (time for 80% of the signal to 
decay to baseline), and k-1, best fit line of first order rate constant of the signal 
return to baseline.  Glutamate and ACh KCl-evoked peaks were volume matched 
(75-100 nL) for data analysis.  Outliers were eliminated from data using a 
Grubb’s test before analyses were conducted.  As data was not always attainable 
at every depth throughout the depth profile due to clogging of the tips of the 
micropipettes, occasional data drop out occurred. Thus, a one-way ANOVA with 
a Bonferroni post hoc test was used to analyze the KCl-evoked data and resting 
levels between glutamate and ACh were analyzed using a two-way ANOVA.  
Correlations were also performed to compare the log of KCl-evoked data and 
resting data for each neurotransmitter. Significance was defined as p < 0.05.     
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Results 
 
Glutamate and Acetylcholine Resting Levels Are Stable Across   
Sub-Regions 
Glutamate and ACh recordings in the mPFC focused on three sub-
regions: the cingulate, prelimbic, and infralimbic.  For both neurotransmitters, 
resting levels were calculated using the self-referenced signals.  When average 
resting levels of glutamate were compared among brain regions (Figure 3.3), 
they were found to be similar (F(2,18) = 0.069; p = 0.93), with only a 0.70 µM 
difference between the highest and lowest levels. Interestingly, analyses of 
average ACh resting levels revealed comparable resting levels (Figure 3.3; 
F(2,17) = 0.47; p = 0.63) of 0.60 – 1.0 µM for the cingulate, prelimbic and 
infralimbic mPFC. There was a significant main effect between the two 
neurotransmitters (F(1,35) = 16; p = 0.0003), however, the resting levels of 
glutamate and ACh were not significantly different within sub-regions of the 
mPFC.  
 
KCl-Evoked Glutamate Release is Similar Among Sub-Regions in the 
Medial Prefrontal Cortex 
KCl-evoked release of glutamate was successfully carried out in the 
cingulate, prelimbic and infralimbic sub-regions of the mPFC. Local application of 
KCl was seen to produce detectable and transient increases in extracellular 
glutamate that lasted for, on average, 3-5 seconds. Representative tracings of 
KCl-induced glutamate release from each brain region were compared (Figure 
3.4) to illustrate the similar peak amplitudes among the sub-regions of the mPFC. 
The tracings indicate the uniformity among signals, with similar peak rise times, 
peak amplitudes, and similar decay profiles.    
The glutamate peak amplitudes, T80 values, and k-1 values were used to 
characterize KCl-evoked release of glutamate.  Measures of glutamate release 
revealed no significant differences in the peak amplitudes of glutamate (Figure 
3.4; F(2,15) = 1.8; p = 0.21) or T80 values (Table I; F(2,16) = 1.9; p = 0.18) in the 
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different sub-regions.  Glutamate k-1 values were also comparable among brain 
regions (Table 3.1; k-1: F(2,16) = 0.31; p = 0.74).  Correlations of the log of KCl-
evoked release of glutamate with resting levels of glutamate were not significant 
for any sub-region of the mPFC (Figure 3.8; cingulate, p = 0.97; prelimbic, p = 
0.12; infralimbic, p = 0.20).     
 
Acetylcholine Signaling Parameters are Similar Among Brain 
Regions 
Studies were carried out to investigate KCl-evoked release of ACh in the 
sub-regions of the mPFC. Similar to the glutamate studies, KCl was seen to 
produce detectable and transient release of ACh lasting 5-10 seconds in the 
mPFC. The similarity among ACh release and uptake from each brain sub-region 
are further illustrated in Figure 3.5.  KCl-evoked ACh peaks rose to peak 
amplitudes in a similar manner, and decayed at similar rates, resulting in 
comparable signaling parameters among the cingulate, prelimbic, and infralimbic 
mPFC.   When ACh signaling parameters were compared among the three brain 
sub-regions, no significant differences were found suggesting homogeneity of 
ACh neurotransmission in the mPFC.   Peak amplitudes showed uniformity, 
(Figure 3.5; F(2,26) = 1.1; p = 0.35) thus further characterizing KCl-induced ACh 
release among the brain sub-regions.  When the log of KCl-evoked releases of 
ACh were correlated with ACh resting levels within each sub-region, a significant 
difference in the cingulate was found (Figure 3.7; Cg1, p = 0.049).  No 
significance was found in either the prelimbic (Figure 3.7; p = 0.93) or the 
infralimbic (Figure 3.7; p = 0.29).  ACh uptake parameters including T80 values 
were also homogeneous (Table 3.2; F(2,23) = 0.32; p = 0.73), as were k-1 values 
(Table 3.2; k-1: F(2,26) = 0.096; p = 0.91).     
 
Comparisons of KCl-Evoked Glutamate and Acetylcholine Reveal 
Significant Differences Between the Neurotransmitters 
We compared the peak amplitudes of both neurotransmitters to contrast 
mPFC glutamate and ACh KCl-evoked release (Figure 3.6).  While significant 
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differences were not found within each neurotransmitter, significant differences 
did exist between neurotransmitters.  ACh peak amplitude measurements ranged 
from 5.3 – 7.1 µM, and glutamate peak amplitude concentrations measured 1.8 – 
2.9 µM.  Analyses revealed that the peak levels of ACh in the cingulate were 
significantly higher than glutamate signals in all sub-regions (F(5,41) = 5.4; p = 
0.0007).  As compared to glutamate levels in the cingulate sub-region, cingulate 
ACh levels were greater by 144%.  KCl-evoked ACh release in the cingulate was 
also greater by 255% and 294% compared to glutamate levels in the prelimbic 
and infralimbic, respectively.     
We also compared T80 values between the two neurotransmitters, and 
found significant differences in decay times between glutamate and ACh (F(5,39) 
= 11; p < 0.0001).  In the cingulate mPFC, ACh decay times were increased 
200% as compared to glutamate decay times in the same brain sub-region 
(Figure 3.6).  ACh T80 values in the prelimbic and infralimbic were increased 
190% and 330% as compared to glutamate values, respectively.    
 
Discussion 
These are the first studies comparing both tonic and phasic release of 
glutamate and ACh levels on a second-by-second time scale in individual sub-
regions of the anesthetized rat mPFC.  The results of our studies demonstrate 
that we can reliably measure both tonic and phasic glutamate and ACh release in 
vivo using the MEA technology.  The spatial resolution of our MEAs allowed for 
the measurement of these neurotransmitters in discrete mPFC sub-regions such 
as the cingulate, prelimbic, and infralimbic, and the sampling rate offered the 
ability to measure individual KCl-induced glutamate and ACh peaks.  
Interestingly, our data support that the glutamate and ACh neurotransmitters 
systems have tonic and phasic release that are uniform within the sub-regions, 
but there were significant differences in both resting and KCl-evoked release of 
glutamate vs. ACh in the mPFC.   
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Resting Levels of Glutamate and Acetylcholine 
These studies did not find significant differences in resting glutamate 
levels within the cingulate, prelimbic, and infralimbic mPFC, although there was 
marked variability within each mPFC sub-region.  We had initially hypothesized 
that we would see differences among the sub-regions for glutamate resting 
levels, as glutamate is tightly regulated in the mPFC (Hascup et al., 2010).  Thus, 
the relative homogeneity of our glutamate resting levels within the mPFC sub-
regions was unexpected, but not unprecedented.  Previous MEA work within our 
lab has shown that glutamate resting levels in anesthetized animals do not differ 
greatly between brain regions.  We have reported resting glutamate levels in 
anesthetized rats of 1.6 ± 0.30 µM in the frontal cortex and 1.4 ± 0.20 µM in the 
striatum, and in the hippocampus, we have measured glutamate concentrations 
ranging from 2.5 µM in the CA1 region to 3.4 μM in the dentate gyrus (Stephens 
et al., 2009). Our glutamate resting levels of 3.7 - 4.3 µM in mPFC sub-regions 
are higher than previously reported levels from MEA studies in other brain 
regions, but not unreasonable.  Resting levels of glutamate that have been 
measured using microdialysis  in the mPFC have ranged from 0.23 ± 0.061 µM to 
3.8 ± 0.40 µM (Del Arco et al., 1998; Ferraro et al., 2001; Hugues et al., 2007; 
Karreman and Moghaddam, 1996; Lupinsky et al., 2010) and 3.0 ± 0.60 µM in 
the striatum (Miele et al., 1996). Compared with microdialysis measures, our 
resting levels of glutamate are over 600% higher than previously reported 
microdialysis glutamate levels in the mPFC of the same strain (Selim and 
Bradberry, 1996).    However, this difference in concentration between MEA 
technology and microdialysis measures can be explained because the MEAs 
sample the extracellular space of the brain directly rather than being separated 
by a membrane containing a net analyte concentration of zero driving diffusion 
into the microdialysis probe. Also, far less edema or gliosis occurs with MEAs 
than microdialysis probes, allowing for better estimates of neuronally-based 
release vs. release from other sources. 
The Pt recording sites on the MEA only measure neurotransmitters that 
come into contact with the surface of the electrode (Burmeister et al., 2000).  We 
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have hypothesized that our increased glutamate resting levels and higher ACh 
resting levels may be the result of the enhanced spatial resolution of our MEAs 
that allows us to be closer to synaptic spillover, as evidenced by studies using 
tetrodotoxin (Day et al., 2006).  Microdialysis probes may be able to pick up 
some spillover, but the size of the probe membranes and the inherent time 
constant of the microdialysis membrane (Schultz and Kennedy, 2008) are 
prohibitive for measuring neurochemical activity at the level of synapses 
(Timmerman and Westerink, 1997).  Thus, the MEAs measure the concentration 
of the neurotransmitter that resides in the extracellular space and do not record a 
fractional level. Our recently reported studies support that this translated to a 5-
10 fold difference of resting levels of glutamate measured by MEAs versus 
microdialysis  in the awake animal and is largely due to the direct measurement 
of the neurotransmitter concentration in the extracellular space by the MEA 
technology (see Hascup et al., 2010).        
In our first paper using MEA technology to measure ACh (Bruno et al., 
2006), we did not report resting levels.  However, in this set of studies we are 
now able to report for the first time in vivo resting levels of ACh using MEA 
technology.  Similar to our glutamate hypothesis, we predicted that we would see 
significant differences in ACh resting levels among the sub-regions of the mPFC.  
We did not find any significant differences in resting levels of ACh among the 
mPFC sub-regions, and little variability existed within each sub-region.  Reported 
resting levels of ACh in the mPFC have widely varied from 0.58 ± 0.14 nM to 3.0 
± 0.3 µM in microdialysis studies (Arnold et al., 2001; Hernandez et al., 2008; 
Huang et al., 2008; Mork et al., 2009; Neigh-McCandless et al., 2002).  Our ACh 
measurements of 0.59 – 0.96 µM fall into the higher end of the range of these 
previously reported microdialysis ACh concentrations. Microdialysis, with its 
collection times on the scale of several seconds to minutes, may allow for more 
ACh hydrolysis by acetylcholinesterase, resulting in lower reported 
concentrations.  Thus, many scientists who use microdialysis for measuring ACh 
levels also perfuse an acetylcholinesterase inhibitor, such as neostigmine, to 
prevent ACh breakdown (Nirogi et al., 2010; Ragozzino et al., 1996).  However, 
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this technique may artificially affect the measured ACh levels in the extracellular 
space. The detection of higher levels of both glutamate and ACh can be 
attributed to the improved spatial and temporal resolution of the MEA. 
The present series of studies was carried out in anesthetized animals to 
take advantage of the brain mapping capability of the MEAs to record glutamate 
and ACh levels in different sub-regions of the mPFC in the same rat. Work from 
our group has shown that the administration of urethane anesthesia to awake, 
freely moving rats resulted in a 58% decrease in resting glutamate levels 
(Rutherford et al., 2007). Thus, it is likely that the anesthetic attenuated 
glutamate resting levels in these studies and possibly affected ACh levels as 
well. Even with this possible attenuation, our glutamate resting levels are still 
relatively high compared to microdialysis studies, but this likely relates to the 
aforementioned properties of the MEA measurements as compared to 
microdialysis.  By contrast, to date we do not have any indication that urethane 
affects KCl-evoked release of glutamate based on our work (data not shown).  
Urethane has also been shown to enhance the actions of the nicotinic ACh 
receptor, but only to a small degree (Hara and Harris, 2002).   Future studies will 
be carried out in the awake animal to circumvent the potential effects of 
anesthesia. It should also be noted that glutamate and ACh levels in the mPFC 
vary with rat strain. For example, glutamate levels in awake rats have been 
reported from 0.22 µM in Sprague-Dawley rats (Ferraro et al., 2001) to 4.2 µM in 
Wistar-King rats (Abekawa et al., 2000).  ACh levels in rats exhibit an even 
greater range of resting levels, from 0.58 nM in awake Sprague-Dawley rats 
(Huang et al., 2008) to 3.0 µM, also in awake Sprague-Dawley rats (Mork et al., 
2009). Thus, the concentrations reported in the present studies were likely 
affected by anesthesia and were likely dependent on the strain used.         
A comparison of our resting levels of glutamate and ACh in mPFC sub-
regions did not reveal any differences within neurotransmitters, but we did see a 
significant main effect between neurotransmitters, suggesting that the 
neurotransmitter resting levels do vary between glutamate and ACh within the 
mPFC.  This may be due to the differential innervation of the mPFC by theses 
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neuronal systems and/or the regulation of these neurons by other neurons and 
signaling molecules.  Interestingly, our resting levels of ACh were extremely 
similar between the prelimbic and infralimbic sub-regions, suggesting that ACh 
regulation is uniform in these areas.  This is supported by microdialysis 
experiments that have sought to characterize sub-regions of the mPFC, and 
have reported similar resting levels between the prelimbic and infralimbic mPFC 
(Hedou et al., 2000).  However, it should be noted that there was overlap 
between sub-regions due to the spatial resolution of the microdialysis technique.    
 
Measurements of KCl-Evoked Release of Glutamate and 
Acetylcholine in the Rat Medial Prefrontal Cortex 
Although no significant differences were found in KCl-evoked glutamate 
release, both the peak amplitudes and the T80 values followed trends along the 
dorsal-ventral axis in the mPFC (Table 3.1).    In previous microdialysis studies 
that used KCl to evoke neurotransmitter release, the infusion of KCl into the 
mPFC resulted in an increase in glutamate levels of 90% (Frantz et al., 2002). 
KCl has also been reported to have no effect on glutamate levels (Welty and 
Shoblock, 2009).  However, these studies were not specific to sub-regions of the 
mPFC, and they did not measure rapid changes in glutamate or ACh.  We saw 
that glutamate peak amplitudes decreased approximately 38% from the cingulate 
to the infralimbic mPFC, while T80 values in the infralimbic mPFC were also 
decreased by 44% as compared to T80 values in the cingulate sub-region.  These 
findings are suggestive of subtle variance in the amounts of glutamate released 
in response to KCl, and in the time needed for 80% signal decay among mPFC 
brain sub-regions that also could relate to the extent of glutamate regulation by 
glutamate transporters located primarily on glia in sub-regions of the mPFC 
(Danbolt, 2001).  Additional studies are needed to further investigate this finding. 
Our studies showed that potassium stimulation was seen to produce 
increases in extracellular ACh that ranged from roughly 500-1000% of the 
baseline or tonic ACh levels. A previous microdialysis study showed that 
potassium stimulation produced an increase in ACh levels of 650% (Herzog et 
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al., 2003).  Thus, the relative change from baseline or tonic ACh levels seen from 
potassium stimulation was in the range of that reported by microdialysis. 
Interestingly, our KCl-evoked ACh peak amplitude values followed a pattern 
similar to that of glutamate along the dorsal-ventral axis of the mPFC.  Both ACh 
peak amplitudes and ACh uptake rates were decreased in more ventral areas as 
compared to dorsal areas.  Our T80 values in the infralimbic sub-region were 
found to be consistent with a previous study using our ceramic based MEAs 
(Bruno et al., 2006). 
When we compared our glutamate and ACh peak amplitudes, we found 
that the ACh peak amplitude concentrations were significantly higher in the 
cingulate region of the mPFC (7.1 µM) than the glutamate concentrations in all 
sub-regions (1.8-2.9 µM).  Acetylcholinesterase distribution in the mPFC is 
known to be heterogeneous (Mrzljak and Goldman-Rakic, 1992; Rajkowska et 
al., 1993). Thus, the varying amounts of this enzyme may be responsible for the 
significant ACh concentration differences.   It has also been shown that the basal 
forebrain projects directly to the cingulate, among other areas of the mPFC (Bigl 
et al., 1982; Houser et al., 1985), and this may account for increased release of 
ACh.  Additionally, the tight regulation of the glutamate signaling (Hascup et al., 
2010) may result in decreased amounts of glutamate release. Our higher 
observed glutamate resting levels may be sufficient to maintain glutamatergic 
tone within the mPFC. Our studies also found significant differences in T80 values 
between glutamate and ACh within all sub-regions.  ACh T80 values in the 
cingulate, prelimbic, and infralimbic mPFC were all significantly increased as 
compared to glutamate T80 values in the same brain sub-regions (Figure 3.6).  
These increased decay times seen in KCl-evoked release of ACh suggest that 
glutamate is being cleared more rapidly than ACh.  This may be due to the 
separate processes that govern the breakdown of these neurotransmitters.  
Glutamate clearance from the extracellular space is dictated by a number of 
factors, including diffusion and the presence of high affinity glutamate 
transporters (Danbolt, 2001).  Extracellular ACh is rapidly broken down by 
endogenous acetylcholinesterase. In addition to diffusion, choline is removed 
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from the extracellular space via sodium dependent high affinity choline 
transporters (Okuda et al., 2000) and through low affinity transport (Meyer et al., 
1982).  Our data suggests that, based on our T80 values, glutamate transport 
may be occurring on a faster time scale than the hydrolysis of ACh and transport 
of choline.     
For these ACh experiments, we used a human recombinant source of 
acetylcholinesterase in our coating solution.  Many studies (Bruno et al., 2006; 
Giuliano et al., 2008) used acetylcholinesterase from an eel source, which 
became unavailable from vendors for a period of time in 2006.  When the eel 
source of acetylcholinesterase was reintroduced, we observed that it had 
markedly lower unit activity than before (≥1000 units/mg of protein), thus limiting 
the ability of the MEAs to measure ACh.  An SDS-PAGE gel analysis of the eel 
source of AChE revealed the presence of possible impurities and/or degradation 
products, in addition to the AChE protein (Figure 3.9; Dr. Luke Bradley, 
unpublished work).  This less reliable form of the enzyme was used for a number 
of experiments, with fairly poor results.  Thus, we were forced to look for an 
alternative source of acetylcholinesterase.  The human recombinant version of 
this enzyme proved to be a viable option for coating, with its higher unit activity 
(≥2000 units/mg of protein).  We feel that the human recombinant 
acetylcholinesterase corrected the previous problems of measuring ACh 
associated with the eel source of acetylcholinesterase. The human recombinant 
acetylcholinesterase, as well as our curing protocol, has allowed us to optimize 
MEAs for in vivo ACh detection (Burmeister et al., 2008) and to carry out the 
studies described in this study.  
The cholinergic system is a complex network that uses and ACh for 
neurochemical signaling.  It has been postulated that the in vivo hydrolysis of 
ACh by acetylcholinesterase occurs so rapidly (Lawler, 1961) that little ACh can 
escape the synaptic cleft intact, and thus measuring choline is a suitable 
alternative (Giuliano et al., 2008).  Our data presented in this paper contradicts 
this hypothesis, as evidenced by our prelimbic resting ACh concentrations of 1.0 
± 0.7 µM, which are at least one order of magnitude higher than the levels of 
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0.058 – 120 nM (Brooks et al., 2007; Del Arco et al., 2007; Huang et al., 2008; 
Prus et al., 2007) reported in recent microdialysis studies performed in the mPFC 
of awake rats. The amplitudes of ACh measured from the KCl-evoked measures 
in this study yielded peak amplitude concentrations of 7.1 ± 3.9 µM, which were 
similar to those previously reported using MEA technology (Bruno et al., 2006).  
Even more impressive, these calculations are based on a self-referenced signal 
that subtracts the background current produced by the breakdown of choline.  
Thus, we can conclude that the subtracted signal likely reflects ACh 
concentrations in the mPFC, and that these ACh levels are robust enough to 
warrant investigations separate from those of choline when they are measured 
on a second-by-second time scale.        
Finally, we sought to examine the relationships between resting levels of 
neurotransmitters and the KCl-evoked release of neurotransmitters.  Over the 
course of analyzing our data, we noticed increased resting levels of glutamate 
with decreased KCl-evoked release of glutamate compared to ACh.  The two 
neurotransmitters almost seemed to have an inverse relationship to each other in 
these two parameters.  We were interested in whether the KCl-evoked release of 
a neurotransmitter was correlated to its resting levels, so we performed 
correlations for each neurotransmitter within the three sub-regions (Figure 3.7).  
The correlation between the log of the evoked release of ACh and resting levels 
of ACh in the cingulate was found to be significant.  We did not see any 
significant correlations in our glutamate data, nor did we find significance in the 
prelimbic and infralimbic sub-regions for ACh.  These findings suggest that the 
tonic and phasic aspects of signaling in the mPFC are independent of each 
other.  However, resting ACh levels may be predictive of KCl-evoked ACh 
release in the cingulate mPFC.                             
 
Conclusions 
In conclusion, we believe that this series of studies is critical to furthering 
our understanding of prefrontal cortex neurochemistry.  We observed no 
significant differences in tonic and phasic release of glutamate or ACh in sub-
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regions of the mPFC.  However, we did see greater amounts of resting glutamate 
compared to resting ACh levels in the three sub-regions of the mPFC. In 
addition, the amount of KCl-evoked ACh release was greater as compared to 
KCl-evoked glutamate release in all sub-regions of the mPFC. Finally, when the 
KCl-evoked signals of glutamate or ACh were expressed relative to baseline, it 
was found that KCl-evoked ACh release was 500-1000 % of baseline whereas 
glutamate was no greater than 100% of baseline, supporting that there was 
evidence for potential autoregulation of both neurotransmitters.  The next step is 
to continue these recordings in awake, freely moving animals with the goal of 
exploring glutamate and ACh signaling in the prefrontal cortex during behavior 
without the potential confound of anesthesia.  Also planned are experiments that 
use drugs such as TTX and TBOA to determine the neuronal contribution to 
glutamate and ACh signals in the mPFC.  Additionally, while these studies used 
separate MEAs to measure glutamate and ACh, the development of a novel MEA 
design that allows for measurement of multiple chemicals of interest at the same 
time (Hascup et al., 2007) should prove to be very useful for determining 
relationships between different neurotransmitter systems in vivo. 
 
Portions of this chapter have been previously published in the manuscript: 
Mattinson, C.E., Burmeister, J.J., Quintero, J., Pomerleau, F., Huettl, P., 
Gerhardt, G.A. 2011. Tonic and phasic release of glutamate and 
acetylcholine neurotransmission in sub-regions of the rat prefrontal cortex 
using enzyme based microelectrode arrays. J Neurosci Methods.  202 (2): 
199-208. 
Permission was obtained from Elsevier for use. 
Copyright © Catherine Elizabeth Mattinson 2012 
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Chapter Three: Figures 
 
Figure 3.1 Microelectrode Array Acetylcholine Coating Schematic 
For the detection of ACh, one pair of sites is coated with human recombinant 
acetylcholinesterase (AChE) and choline oxidase (ChOx), while the other is 
coated with only ChOx.  When ACh comes into contact with the enzyme layers, 
AChE hydrolyzes ACh into choline and acetate.  The choline is in turn oxidized 
by the ChOx into H2O2 and betaine.  Similar to the glutamate MEA, the H2O2 is 
oxidized at the Pt site producing a signal current that is directly proportional to 
the concentration of choline.  mPD is used to exclude electroactive interferents 
such as AA.  The sentinel ChOx coated sites generate a choline signal, which is 
subtracted from the combined ACh/choline signal, resulting in a self-referenced 
ACh signal for measures of ACh resting levels.             
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Figure 3.3 Microelectrode Array Placement in the Medial Prefrontal Cortex 
Histological section with cresyl violet staining showing minimal damage produced 
by the MEA. Histological sections were used to confirm placement in the mPFC 
cingulate (Cg1), prelimbic (PrL), and infralimbic (IL).  Adapted from Paxinos and 
Watson, 2009.  
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Figure 3.4 Resting or Tonic Levels of Glutamate and Acetylcholine in Sub-
Regions of the Medial Prefrontal Cortex 
A) Resting levels of glutamate were homogeneous and not significantly different 
within sub-regions of the mPFC. (n = 7 for all regions). B) Resting levels of ACh 
were not significantly different within sub-regions of the mPFC (Cg1 and IL, n = 6; 
PrL, n = 8).  Each color represents a different animal within both 
neurotransmitters.   
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Figure 3.5 KCl-Evoked Glutamate Release in the Medial Prefrontal Cortex   
A) Shown are representative signals from the Cg1, PrL and IL of the mPFC. The 
arrow marks the ejection of KCl to evoke phasic release of glutamate. B) Graphs 
showing the maximum amplitudes of KCl-evoked release in the different sub-
regions of the mPFC. The average amplitudes of KCl-evoked glutamate release 
were not significantly different in the three brain regions.  Each color represents a 
different animal. 
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Figure 3.6 KCl-Evoked Acetylcholine Release in Sub-Regions of the Medial 
Prefrontal Cortex 
A) Shown are single traces of KCl-evoked ACh release from the Cg1, PrL and IL 
of the mPFC. The arrow marks the ejection of KCl to evoke phasic release of 
Ach. B) Graphs showing average amplitudes of KCl-evoked ACh release in the 3 
sub-regions of the mPFC. There was no significant difference in the ACh 
amplitudes within the different sub-regions along the dorsal-ventral axis of the 
mPFC. (Cg1 and PrL, n = 10; IL, n = 9).  Each color represents a different 
animal.  
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Figure 3.7 Comparisons of Glutamate and Acetylcholine Peak Amplitudes and 
T80 Values in Different Sub-Regions of the Medial Prefrontal Cortex 
A) Significant differences were found between the KCl-evoked ACh signal 
amplitudes (orange circles) in the Cg1 (**p < 0.01; *p < 0.05; Glu: n = 6; ACh: 
Cg1 and PrL, n = 10, IL, n = 9) as compared to glutamate signaling (green 
squares) in the three sub-regions of the mPFC.  B) T80 values differ significantly 
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between glutamate and ACh in each sub-region (***p < 0.001; **p < 0.01; *p < 
0.05; Glu: Cg1 and IL, n = 6, PrL, n = 7; ACh: Cg1 and PrL, n = 9, IL, n = 8).  
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Figure 3.8 Correlations of Glutamate and Acetylcholine Peak Amplitudes and 
Resting Levels 
A, B, C) The correlations of the log of KCl-evoked glutamate peak amplitudes 
and glutamate resting levels were not significant (Cg1 and PrL, n = 5; IL, n = 5).  
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D, E, F)  The log of KCl-evoked ACh peak amplitudes and ACh resting levels 
showed a significant correlation in the Cg1 sub-region of the mPFC (p < 0.05).  
Other sub-regions did not show any significant correlations (Cg1 and IL, n = 6; 
PrL, n = 8).       
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Table 3.1 KCl-Evoked Glutamate Release Data 
 
Sub-region Peak 
Amplitude 
T80 Value k-1 
Cg1 2.9 ± 0.9 µM 3.2 ± 1.8 s 0.7 ± 0.7 s-1 
PrL 2.0 ± 1.1 µM 3.0 ± 1.2 s 0.6 ± 0.9 s-1 
IL 1.8 ± 1.1 µM 1.8 ± 0.6 s 0.8 ± 0.9 s-1 
Peak amplitudes, T80 values, and k-1 values for each of the three sub-regions 
highlight the homogeneity of the mPFC (mean ± SD; Cg1 and IL: n = 6; PrL: peak 
amplitude, n = 6, T80 value and k-1, n = 7).  
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Table 3.2 KCl-Evoked Acetylcholine Release Data 
 
Sub-region Peak 
Amplitude 
T80 Value k-1 
Cg1 7.1 ± 3.9 µM 6.3 ± 1.7 s 0.3 ± 0.4 s-1 
PrL 5.3 ± 2.4 µM 5.7 ± 1.5 s 0.3 ± 0.3 s-1 
IL 5.3 ± 2.7 µM 6.0 ± 1.9 s 0.3 ± 0.3 s-1 
Peak amplitudes, T80 values, and k-1 values for each of the three sub-regions 
highlight the homogeneity of the mPFC, and ACh release data (mean ± SD; Cg1 
and PrL: peak amplitude and k-1, n = 10, T80 value, n = 9; IL: peak amplitude, and 
k-1, n = 9, T80, n = 8). 
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Chapter Four: Glutamatergic Recordings in the Infralimbic Prefrontal 
Cortex of Awake Freely Moving Rats:  
Circadian Data and Phasic Glutamate Signaling 
 
Introduction 
 Microdialysis has traditionally been used to measure in vivo 
neurotransmission.  However, with collection times in the range of minutes 
(Nandi and Lunte 2009), microdialysis is unable to measure phasic changes in 
glutamate signaling.  MEA technology can sample glutamate concentrations in 
vivo on a sub-second time scale (Burmeister, Pomerleau et al. 2002), thus 
greatly improving upon the temporal resolution of microdialysis.  This advanced 
temporal resolution is necessary for the detection of glutamate ‘transients’.  
Transients are rapid, dynamic increases in glutamate that have been observed in 
multiple brain regions and multiple rat strains using MEAs (Hascup, Hascup et al. 
2011).    
In addition to the temporal advantages of MEAs, this technology allows for 
the measurement of distinct brain sub-regions including the infralimbic mPFC, as 
the MEA only measures substances that come into contact with the surface of 
the Pt recording sites (Burmeister, Moxon et al. 2000).  Rutherford et al. 
demonstrated the ability to modify MEA technology for use in the awake freely-
moving animal, thus allowing for simultaneous measurements of glutamate and 
behavior (Rutherford, Pomerleau et al. 2007).  The advanced spatial resolution of 
the MEA and these modifications will allow us to record glutamate signaling from 
the infralimbic mPFC on a sub-second time scale without the confound of 
anesthetic.    
The infralimbic sub-region of the mPFC was investigated in these studies.  
The infralimbic mPFC is a ventral portion of the mPFC that has been shown to be 
important for working memory (Ragozzino and Kesner 1998; Delatour and 
Gisquet-Verrier 1999), attention (Birrell and Brown 2000), goal-directed behavior 
(Killcross and Coutureau 2003), impulsivity (Murphy, Dalley et al. 2005), and 
extinction (Morgan and LeDoux 1995; Morgan and LeDoux 1999; Peters, 
LaLumiere et al. 2008).  Glutamatergic neurotransmission in the infralimbic 
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mPFC has not been well characterized in the awake, freely moving animal.  The 
poor spatial resolution of microdialysis probes has been prohibitive in measuring 
specific sub-regions of brain structures.  Thus the infralimbic and prelimbic areas 
of the mPFC have typically been grouped together as the ventral mPFC (Dalley, 
Cardinal et al. 2004), despite the possibility that differential glutamate signaling 
may exist between these two regions.   
The infralimbic mPFC receives input from the suprachiasmatic nucleus 
(SCN) via the paraventricular thalamic nucleus (Sylvester, Krout et al. 2002).  As 
the SCN serves as the circadian pacemaker of the brain (Kalsbeek, Palm et al. 
2006), we extended our awake freely-moving glutamate recordings to 24 hour 
time periods to investigate the possibility of circadian influences on glutamate 
neurotransmission in the infralimbic mPFC.   
We hypothesized that we would be able to detect rapid, dynamic 
glutamate transients in the infralimbic mPFC using MEA technology, as well as 
measure tonic glutamate levels.  We also hypothesized that we would see 
changes in glutamate signaling related to the light and dark cycles during a 24 
hour time period.   
 
 
Materials and Methods 
 
Animals 
Male F344 rats, aged 3-6 months were used in these studies (for care, 
see Animals).  Animals were maintained on a 12 h light: 12 h dark cycle (lights on 
at 06:00 h).  During the 24 hour recordings, animals had ad libitum access to 
water and food in the recording chambers.  Following MEA implant surgery, 
animals were monitored and weighed daily.  If an animal weighed less than 80% 
of its pre-surgery weight, recordings were not performed that day.   
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Microelectrode Array Preparation 
To optimize the MEA for chronic recordings, the MEA circuit board was 
minimized, and the MEA was epoxied to a plug/connector assembly 
(Microelectrode Array Configuration and Preparation – Modifications for Awake 
Freely-Moving Recordings).  MEAs were made selective for glutamate through 
the use of glutamate oxidase coating layers (Microelectrode Array Configuration 
and Preparation – Microelectrode Array Coatings).  For in vivo chronic 
recordings, Nafion® was used as the exclusion layer (Microelectrode Array 
Configuration and Preparation – Exclusion Layers) to prevent electroactive 
interferents from coming into contact with the Pt recording sites.  Prior to 
implantation, MEAs were calibrated in vitro (Microelectrode Array Calibrations).  
For awake freely-moving MEAs, the calibrations were performed within the 
recording chamber to best simulate the environment in which the recordings 
would take place.  After calibration, MEA ceramic tips and reference electrodes 
were soaked in phosphate buffered saline (PBS; 0.05 M) until the implantation 
surgery.           
 
Microelectrode Array Implant Surgery 
MEA implant surgery procedures are described in Microelectrode Array 
Implant Surgery and Recordings – Awake Freely-Moving Surgery Procedures.  
Surgical tools were autoclaved for the first surgery of the day, and sterilized in a 
glass bead sterilizer for any subsequent surgeries.  Total time for each surgery 
was approximately one hour.  
 
Awake Freely-Moving Recordings 
All recordings were performed at 4 Hz.  Typically, each animal underwent 
two 24 hour recording sessions.  Recordings were carried out as described in 
Microelectrode Array Implant Surgery and Recordings – Awake Freely-Moving 
Recordings.  Animals were connected and allowed to baseline for approximately 
one hour before the 24 hour recording session began.  During the recording 
session, animals remained in the recording chambers within a sound-isolated 
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room.  The experimenter occasionally entered the room during the light cycle to 
monitor the animal and check to ensure that the tether was not tangled.  After the 
24 hour recording session, the animal was returned to its home cage for a 
minimum of 20 hours before the second 24 hour recording session was carried 
out.  
  
Locomotor Activity Monitoring 
During the experiments, animals were placed in a Digiscan animal activity 
monitoring device inside of the recording chamber.  Multiple parameters of 
locomotion, including distance traveled and number of movements, were 
measured in five minute time bins over the course of the 24 hour sessions using 
Oasis software.  Locomotor activity was measured for the entire duration of 
electrochemical recording sessions.  After a recording session, the recording 
chamber was cleaned with Roccal disinfectant (Pfizer, Inc., New York City, NY). 
 
Histology 
After the experiments, animals euthanized under heavy anesthesia and 
their brains were removed to check for MEA placements.  For details, see 
Histology.  Animals with MEA placements outside of the IL cortex were excluded 
from data analysis.   
 
Data Analysis and Statistics 
Collected data were processed using a custom Matlab®-based analysis 
package (Data Collection).  Data parameters of interest included resting levels of 
glutamate, glutamate peak amplitudes, T80 values, and uptake rates.  To 
examine phasic glutamate activity, recordings were scanned using a peak finder 
tool with a threshold set at a minimum of a signal-to-noise ratio of 2.5.  A one-
way repeated measures ANOVA with a Bonferroni post hoc test was used for 
analyses, as were correlation statistics.  Significant was defined as p < 0.05.   
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Results 
24-Hour Signaling Parameters Show Significant Effects 
Variable resting levels of glutamate (15 min bins of average glutamate 
resting levels were averaged together for the light and dark cycles; average ± 
SD: light 10 ± 20 µM, dark 8.7 ± 12 µM) both increase and decrease over a 24-
hour period, and a significant effect of time was found on glutamate resting levels 
(F(4,95) = 220; p < 0.0001; n = 5).  Bonferroni post hoc comparisons revealed 
significant differences between all animals.  24-hour recordings in the infralimbic 
area of the mPFC show the number of transients (Figure 4.1) in a 15 minute 
period varying, on average, between 10 and 40 events.  Analyses revealed a 
significant effect of time on number of glutamate transients (F(4,95) = 37; p < 
0.0001; n = 5), and Bonferroni post hoc comparisons showed significant 
differences between all animals, except for green and blue, green and black, and 
purple and orange  Additionally, the peak amplitude concentration of the 
transients showed a significant effect of time on glutamate transient peak 
amplitudes (F(3,95) = 180; p < 0.0001; n = 4).  Bonferroni post hoc comparisons 
revealed significant differences between all animals, except purple and orange.   
 
Significant Correlations Exist Between Glutamate Signaling 
Parameters 
Negative correlations exist between glutamate concentrations and the 
number of glutamate events (Figure 4.2) during both the light (R2 = 0.15; p = 
0.0001; n = 4) and dark cycles (R2 = 0.047; p = 0.044; n = 4).  Distance traveled 
and glutamate concentrations also negatively correlated during the light cycle 
(Figure 4.3; R2 = 0.099; p = 0.0010; n = 5), but did not correlate during the dark 
cycle.  Distance traveled did not correlate with the number of glutamate events 
during either portion of the light cycle.    
 
Discussion 
 This set of experiments sought to further our understanding of tonic and 
phasic aspects of glutamate signaling in the infralimbic sub-region of the mPFC 
 
 
 
64
over the course of a circadian cycle.  Our studies confirmed the existence of 
rapid, dynamic transient glutamate signaling events in the infralimbic mPFC.  We 
also observed significant effects over the 24 hour recording period.  Finally, 
correlations were revealed between transient events and transient glutamate 
peak amplitude concentrations, and between locomotor activity and transient 
glutamate peak amplitude concentrations.  These findings suggest relationships 
among aspects phasic glutamate signaling and locomotion in the infralimbic 
mPFC.   
Glutamate Resting Levels Vary Among Individual Animals 
  When glutamate resting levels were analyzed over a 24 hour time period, 
we did not find patterns of signaling that indicated a circadian influence on 
glutamate neurotransmission.  Previous work using microdialysis has resulted in 
mixed outcomes. Using polygraphic recordings to determine activity states, 
studies have reported no change in glutamate levels in the mPFC (Lena, Parrot 
et al. 2005), as well as an increase in glutamate levels during REM sleep in the 
orbitofrontal cortex (Lopez-Rodriguez, Medina-Ceja et al. 2007).  Another study 
using MEA technology to measure glutamate during the sleep cycle showed 
increased glutamate levels during waking and REM sleep in the infralimbic 
mPFC, and reported resting glutamate concentrations of 15 ± 4.1 µM (Dash, 
Douglas et al. 2009).  Our reported resting levels of glutamate in the infralimbic 
sub-region ranged from approximately 1 µM to 20 µM among five animals, with 
averages of 10 µM and 9 µM during the light and dark cycles, respectively.  Our 
averages differ from those of Dash et al. due to differences in circadian 
quantification and strain.  We analyzed our data in terms   of the light and dark 
cycles of a 24 hour time period, whereas Dash and colleagues used EEG and 
EMG to monitor animal activation states.  Additionally, our experiments were 
performed in F344 rats while their research used Wistar Kyoto rats.  Wistar Kyoto 
rats originating at Charles River Laboratories have been postulated to be a 
model of the inattentive type of ADHD, and unpublished work from our lab has 
reported increased resting glutamate levels and evoked glutamate release in the 
PFC as compared to control strains.  When we examined individual animals 
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(Figure 4.1, D; each color represents a different animal, and the color was 
consistent over all figures), we found that two animals showed decreasing 
glutamate levels over the 24 time period (purple decreased by 54%, blue 
decreased by 33%), one animal showed increasing levels (black increased by 
38%), one animal remained relatively constant (orange decrease by 11%), and 
one animal had relatively large fluctuations in resting levels of glutamate (green).  
These differences underscore the potential for variability among individual 
animals, and the MEA’s ability to measure these differences.       
We have previously reported glutamate resting levels of 3.7 µM in the 
infralimbic mPFC of urethane-anesthetized rats (Mattinson, Burmeister et al. 
2011).  The 270% increase in our freely-moving resting glutamate levels of 10 
µM as compared to anesthetized resting glutamate levels can be accounted for 
by the effects of anesthesia.  Our laboratory has shown that urethane anesthesia 
administration resulted in significantly decreased resting levels of glutamate 
(Rutherford, Pomerleau et al. 2007).  Additionally, it should be noted that 
anesthetized studies sampled the infralimbic mPFC from two depths, -4.5 and -5 
mm, while awake freely-moving studies only sampled from one depth, -4.5 mm.    
This difference in the area of the infralimbic mPFC that was sampled for these 
experiments may account for some of the differences in glutamate resting levels 
between the anesthetized and awake studies as well.       
  
Glutamate Transients and Peak Amplitudes Are Not Influenced By 
the Circadian Cycle 
  Following recording sessions, data were examined for the presence of 
transient glutamate signaling events.  These phasic changes in glutamate are 
characterized by their rapid time course, their intermittent appearance during a 
recording, and their signal that is only recorded on MEA sites that are coated for 
glutamate detection.  It is hypothesized that these glutamate transients are the 
result of synaptic spillover.  Due to the advanced spatial and temporal resolution 
of the MEA, synaptic spillover can be detected to a degree never before 
reported.  Hascup and colleagues were the first to report these dynamic changes 
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in glutamate neurotransmission as measured by MEA technology (Hascup, 
Hascup et al. 2011), but another group using biosensors has also recently 
reported the presence of these transients in the amygdala (Wassum, Tolosa et 
al. 2012).  This group also reported an increase in the number of transients 
during a lever pressing task, and concluded that glutamate transients may be 
important for decision making processes.  The experiments in this chapter sought 
to measure glutamate transients over the course of a 24 hour time period.  Our 
data did not reveal any significant patterns in transient glutamate signaling 
corresponding to the circadian cycle.  However, our studies provide further 
support for the existence of this dynamic phenomenon (see inset of Figure 4.4). 
 Peak amplitude concentrations of glutamate transients were also 
quantified over the circadian cycle.  Once again, patterns associated with the 
light and cycle did not emerge during analysis.  Our peak amplitude 
concentrations averaged 1.9 µM for the light cycle, as well as 1.9 µM for the dark 
cycle, thus indicating a uniformity of glutamate transient peak amplitudes over 
the course of 24 hours.  Interestingly, these concentrations are similar to the KCl-
evoked 1.8 µM average peak amplitude concentration we reported in a previous 
study in the infralimbic mPFC (Mattinson, Burmeister et al. 2011).  This indicates 
that glutamate release in the infralimbic sub-region is not affected by urethane 
anesthesia, as the concentrations are consistent between anesthetized and 
awake freely-moving experiments.  Additionally, the similar peak amplitudes of 
KCl-evoked release and glutamate transients suggest a similar regulation.  
 
Correlations Exist Between Glutamate Signaling Parameters and 
Locomotion   
  To further examine relationships between glutamate signaling 
parameters, we performed a series of correlations on our data for both the light 
and dark portions of the circadian cycle.  When the number of glutamate 
transients was compared to the peak amplitudes of those transient events, we 
found significant negative correlations in both the light and dark cycles.  
Glutamate transients have been shown to be TTX dependent, thus suggesting 
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vesicular glutamate release (Wassum, Tolosa et al. 2012).  As glutamate 
transients increased in frequency in our experiments, transient peak amplitude 
concentrations decreased, most likely due to the decreased time available to 
repackage glutamate before the next transient event.  This finding is consistent 
with the tight regulation associated with in vivo glutamate signaling (Danbolt 
2001).        
 Locomotor activity, defined as distance traveled, was also compared to 
glutamate transient peak amplitudes, and a significant negative correlation was 
only found during the light cycle.  Thus, we observed a decrease in transient 
peak amplitude associated with increased movement.  This relationship was not 
observed during the dark cycle.  From examining the data, we can see that 
overall movement was increased during the dark cycle, as expected with a 
nocturnal species such as rats, but transient glutamate concentrations remained 
relatively consistent.  Locomotor activity was also compared to the number of 
glutamate transients during the dark cycle, and no significant relationships were 
found (data not shown).  These findings indicate that locomotor activity 
associated with dark portion of the circadian cycle is independent from transient 
glutamate signaling.  As transient increases in glutamate are only recently 
reported, and only one other study has used MEAs to measure glutamate over a 
24 hour time period (Dash, Douglas et al. 2009), it is difficult to compare our 
findings to existing literature.      
 
Conclusion 
 These experiments have not only confirmed the presence of transient 
glutamate signaling in the infralimbic mPFC, but have also characterized 
glutamate signaling over a 24 time course.  While a consistent pattern of 
glutamate signaling corresponding to changes in the circadian cycle did not 
emerge, we did observe significant relationships between signaling parameters 
during both the light and dark cycles of a 24 time period.  These data indicate 
that the circadian influence on infralimbic glutamate levels should not be 
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considered a confound in future experiments, and the SCN may not exert a 
strong impact on glutamatergic signaling in the infralimbic mPFC.    
 
Copyright © Catherine Elizabeth Mattinson 2012 
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Chapter Four: Figures 
 
 
 
Figure 4.1 24-Hour Glutamate Neurotransmission Signaling Parameters 
24-hour traces of glutamate signaling parameters revealed significant effects.  A 
significant effect of time on glutamate resting levels (A; all animals averaged; p < 
0.0001; n = 5) was found, and a significant effect of time on the number of 
glutamate transients was also revealed (B; all animals averaged; p < 0.0001; n = 
5).   There was also a significant effect of time on the transient peak amplitude 
concentrations (C; all animals averaged; ***p < 0.001; n = 4).  Individual traces of 
each animal’s signaling parameters reveal heterogeneity among animals (D; 
each color represents a different animal).                    
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Figure 4.2 Number of Glutamate Events and Concentration Correlate 
The number of transient glutamate events was correlated to the concentration of 
those glutamate events in both the light (A; R2 = 0.15; ***p < 0.001; n = 4) and 
dark (B; R2 = 0.047; *p < 0.05; n = 4) portions of the 24-hour cycle.  Each color 
represents a different animal. 
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Figure 4.3 Locomotor Activity Correlates with Glutamate Concentration During 
the Light Cycle 
When the distance traveled by an animal was correlated to the concentrations of 
the glutamate peaks, a negative correlation was found during the light cycle (A; 
R2 = 0.099; **p < 0.01; n = 5).  The dark cycle did not show a significant 
correlation.  Each color represents a different animal.  
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Chapter Five: The Effects of Methylphenidate Treatment on Tonic 
and Phasic Glutamate Levels in Sub-Regions of the Rat Medial 
Prefrontal Cortex 
 
Introduction 
The mPFC is an area of the brain that is critically important for complex 
cognitive processes including attention, memory, learning, organization, and 
integration.  These processes are often interrupted or dysfunctional in the 
development and maintenance of drug addiction.  The abuse of stimulants in 
particular may result in behavioral sensitization, a hypersensitivity caused by 
repeated psychostimulant administration (Kalivas and Stewart 1991; Gaytan, al-
Rahim et al. 1997; Dafny and Yang 2006).  Thus, behavioral sensitization has 
been proposed as a model of drug seeking (Robinson and Berridge 1993; 
Hotsenpiller and Wolf 2002).  Cocaine and amphetamine studies have implicated 
the PFC in the development of behavioral sensitization (Pierce, Reeder et al. 
1998; Tzschentke and Schmidt 1998; Cador, Bjijou et al. 1999; Li, Hu et al. 1999; 
Liao and Lin 2008). Recently, Lee and colleagues also demonstrated that the 
PFC was required for the development of behavioral sensitization associated 
with MPH administration (Lee, Swann et al. 2008).        
MPH is a stimulant drug that is commonly prescribed for the treatment of 
attention-deficit hyperactivity disorder (Challman and Lipsky 2000; Swanson and 
Volkow 2002; Askenasy, Taber et al. 2007).  MPH has also been shown to have 
abuse potential.  Rats will self-administer MPH (Botly, Burton et al. 2008; 
Marusich and Bardo 2009; Marusich, Beckmann et al. 2010), and rats exposed to 
MPH as adolescents will more readily adapt to cocaine administration as adults 
(Brandon, Marinelli et al. 2001; Crawford, Baella et al. 2011; Harvey, Sen et al. 
2011).    
To further investigate the effects of an abused stimulant medication on the 
mPFC, a high dose of MPH was chronically administered to rats.  After an 
administration period and a rest period, glutamate was measured in three sub-
regions of the mPFC: the cingulate cortex, the prelimbic cortex, and the 
infralimbic cortex.  Glutamate is the major excitatory neurotransmitter in the 
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central nervous system, and mPFC glutamate is intimately associated with and 
influenced by brain circuitry that is implicated in the development of drug 
addiction.  Stimulants such as cocaine and amphetamine have both been shown 
to increase PFC glutamate (Reid, Hsu et al. 1997).  Three sub-regions of the 
mPFC were examined in an effort to detect any heterogeneous responses to 
MPH treatment within the mPFC.   
These experiments employed the use of MEA technology to measure both 
tonic and phasic aspects of glutamate signaling in the mPFC.  We hypothesized 
that MPH would differentially affect glutamate neurotransmission in mPFC sub-
regions.  The improved spatial and temporal resolution of the MEA allowed for an 
advanced characterization of resting glutamate levels and KCl-evoked glutamate 
release in the three distinct sub-regions of the mPFC. Thus, we were able to 
report, for the first time, the effects of MPH treatment on tonic and phasic 
glutamate signaling in the mPFC.   
      
Materials and Methods 
Animals 
Male Sprague-Dawley rats (Harlan, Indianapolis, IN) aged 3-6 months 
were used for all experiments (n=11).  For care, see Animals.   
 
Methylphenidate Chronic Treatment 
Chronic treatment of the rats with MPH prior to in vivo MEA recordings 
was carried out by Dr. Julie Marusich of the University of Kentucky.  Rats 
received daily MPH (10 mg/kg in saline, s.c.) or saline injections for ten 
consecutive days.  Following the ten day treatment period, rats rested for seven 
days.  Recordings were performed the day after the rest period (day 18 from the 
start of the MPH injections).      
 
Locomotor Monitoring 
Activity monitoring was performed by Dr. Julie Marusich of the University 
of Kentucky.  After receiving their daily injection, rats were placed in activity 
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monitoring chambers for one hour.  The distance traveled in centimeters was 
averaged in five minute bins over the course of the hour, and then the bins were 
averaged to obtain the average distance traveled per five minutes for each rat on 
each day.   
 
Microelectrode Preparation 
MEAs for acute anesthetized recordings were made selective for 
glutamate through enzyme coatings (see Microelectrode Array Configuration and 
Preparation – Microelectrode Array Coatings), and an electroplated layer of mPD 
(described in Microelectrode Array Configuration and Preparation – Exclusion 
Layers).  Prior to the experiment, in vitro calibrations (detailed in Microelectrode 
Array Calibrations) were performed to determine the slope, selectivity, limit of 
detection, and linearity of the MEAs.  After calibration, a glass micropipette was 
affixed to the MEA to allow for intracranial delivery of KCl (see Application of 
Intracranial Solutions).       
 
In Vivo Recordings 
Acute anesthetized recordings were performed as previously described 
(see Microelectrode Array Implantation Surgery and Recordings – Anesthetized 
Surgery Procedures and – Anesthetized Recordings).  On the day of surgery, 
rats were anesthetized with urethane and the surgery was performed.  The 
micropipette attached to the MEA was filled with an isotonic KCl solution (70 mM 
KCl, 79 mM NaCl, 2.5 mM CaCl2 • 2H2O; pH = 7.4) and connected to a 
Picospritzer III (Parker Hannifin Corp, NJ) to allow for local applications of KCl 
into the extracellular space . The MEA/micropipette assembly was lowered into 
the mPFC (AP: +3.2 mm; ML: ±0.8 mm; DV: -1.5 to -5 mm; from bregma 
(Paxinos and Watson, 2009) using a Narishige MO-10 microdrive.  The MEA 
assembly was lowered in 0.5 mm increments and recordings were taken at each 
depth to record glutamate levels along the dorsal-ventral axis of the mPFC. Once 
lowered into place, basal levels were established over ten minute recording 
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durations, and then KCl solution was ejected (75-100 nl) to evoke glutamate 
release.    
 
Histology 
After the experiment, rats were euthanized under heavy anesthesia, and 
microelectrode array placements were confirmed.  For detailed procedures, see 
Histology. 
 
Data Analysis 
Collected data were processed using a custom Matlab®-based analysis 
package (Data Collection).  Data parameters analyzed were resting (tonic 
release) glutamate levels (average of the ten data points prior to the first ejection 
at each depth) and data from KCl-evoked release (phasic release) of glutamate 
that included: peak amplitude, T80 (time for 80% of the signal to decay to 
baseline), and k-1, best fit line of first order rate constant of the signal return to 
baseline.  Glutamate KCl-evoked peaks were volume matched (75-100 nL) for 
data analysis. As data was not always attainable at every depth throughout the 
depth profile due to clogging of the tips of the micropipettes, occasional data drop 
out occurred.  For locomotor data, a two-tailed paired t-test was used for 
analysis.  Resting glutamate levels and phasic glutamate signaling parameters 
were analyzed using both a one-way repeated measures ANOVA and individual t 
tests.  Significance was defined as p < 0.05. 
 
Results 
Methylphenidate Treated Rats Show Increased Locomotor Activity 
After receiving their MPH or saline injections, rats were placed in 
locomotor activity monitoring chambers to investigate the effects of treatment on 
behavior.  Rats treated with MPH showed significant increases in distance 
traveled as compared to saline controls (Figure 5.1; t(9) = 12; p < 0.0001).  On 
average, rats treated with MPH moved approximately 1200 cm more than their 
saline treated counterparts within each five minute time bin.     
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Resting Levels of Glutamate Are Similar Between Treatment Groups 
When resting levels in the cingulate, prelimbic, and infralimbic cortex were 
compared between rats chronically treated with MPH and their saline 
counterparts, no significant differences were found (Figure 5.2).  Both a one-way 
repeated measures ANOVA (F(5,21) = 2.0; p = 0.12; saline, n = 4; MPH, n = 5) 
and individual t tests were employed to check for significant differences between 
the groups.  On average, the difference between the two treatment groups’ 
glutamate resting levels was 1.8 µM, although this difference was not significant.     
 
Phasic Glutamate Signaling Shows Homogeneity in All Sub-Regions 
Phasic glutamate signaling parameters including peak amplitudes, T80 
values, and uptake rates were analyzed within each sub-region of the mPFC.  
Peak amplitudes (Figure 5.2) did not differ significantly between MPH chronically 
treated rats and saline controls in any of the three sub-regions explored (F(5,21) 
= 0.30; p = 0.91; saline, n = 4; MPH, n = 5).  T80 values were also found to be 
similar among the three sub-regions and between the treatment groups (Figure 
5.3; F(5,21) = 1.1; p = 0.40; saline, n = 4; MPH, n = 5).  Uptake rates did not vary 
significantly between the two treatment groups, nor among any of the sub-
regions as well (Figure 5.3; F(5,21) = 0.44; p = 0.82; saline, n = 4; MPH, n = 5).  
For a summary of these data, see Table 5.1. 
 
Discussion 
 These studies, to our knowledge, are the first to characterize glutamate 
signaling in the mPFC after chronic MPH treatment.  The use of MEA technology, 
with its advanced spatial resolution, allowed for measurements of glutamate in 
distinct sub-regions of the mPFC in the same animal.  The temporal resolution of 
the MEA technology allowed us to detect second-by-second changes in KCl-
evoked phasic glutamate signaling within the cingulate, prelimbic, and infralimbic 
mPFC, thus revealing a more complete picture of dynamic changes in glutamate 
neurotransmission.  Our results reflect our previous work (Mattinson, Burmeister 
 
 
 
78
et al. 2011), with similar glutamate levels and signaling parameters among the 
three sub-regions investigated.  Significant differences in locomotor behavior 
existed between chronic MPH-treated and saline-treated groups, but no 
differences in glutamate signaling existed.         
 
Locomotor Effects of MPH Treatment 
The behavioral effects of stimulant treatment are generally predictable, 
and have been well established.  Cocaine, methamphetamine, and amphetamine 
were all shown to increase locomotor activity in mice in early studies (Dews 
1953; Smith 1965), and  Hughes and others reported increased motor activity 
and rearing in rats receiving MPH (Hughes 1972; Bhattacharyya, Ghosh et al. 
1980).  MPH administration increases extracelluar dopamine by blocking the 
dopamine transporter (Ritz, Lamb et al. 1987; Heron, Costentin et al. 1994; Pan, 
Gatley et al. 1994; Wayment, Deutsch et al. 1999), and this increase in 
extracellular dopamine is thought to be responsible for increases in motor activity 
(Rebec 2006).  As lesion studies have shown, stimulant-induced increases in 
locomotion are associated with these drugs’ effects on the mesolimbic 
dopaminergic system, particularly in the nucleus accumbens (Kelly 1975; Joyce 
and Koob 1981; Koob, Stinus et al. 1981).  We also observed that over the ten 
day treatment period, distance traveled increased an average of 1000 cm in the 
MPH treated animals.  This increase in locomotor activity is consistent with 
behavioral sensitization in response to chronic MPH treatment (Crawford, 
McDougall et al. 1998; Yang, Amini et al. 2003; Wooters, Dwoskin et al. 2006; 
Wooters, Bardo et al. 2011).  Thus, the increased locomotor behavior in 
chronically MPH-treated rats in this study was as we anticipated.  This increase 
in activity served as a positive control, assured that the dose of MPH was 
appropriate, and that the animals were responding as expected to the drug.          
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Resting Levels of Glutamate Show Similarity Between Treatment 
Groups 
 In these experiments, we examined the glutamate resting levels of 
chronically MPH-treated rats and controls in three sub-regions of the mPFC.  
Chronically MPH-treated rats averaged resting glutamate levels of 4.8 µM, 4.1 
µM and 3.2 µM in the cingulate, prelimbic, and infralimbic mPFC, respectively.  In 
comparison, chronically saline-treated rats showed glutamate resting levels of 
2.8 µM in the cingulate, 2.0 µM in the prelimbic, and 2.0 µM in the infralimbic.  No 
significant differences were found among mPFC brain sub-regions within each 
treatment group.  However, this information is consistent with our previous work 
(Mattinson, Burmeister et al. 2011).  Measurements of glutamate in the mPFC of 
F344 rats revealed a homogeneity of glutamate resting levels among mPFC sub-
regions.  We have postulated that these similarities are due to uniform regulation 
of tonic and phasic glutamate dynamics within the mPFC.   
Our chronically saline-treated animals showed glutamate resting levels 
that were increased by a minimum of 100% as compared to other reported 
mPFC resting glutamate levels in Sprague-Dawley rats (Welty and Shoblock 
2009; Roenker, Gudelsky et al. 2011).  The difference in these glutamate resting 
level concentrations can best be accounted for by the difference in technologies 
used for measurement.  Our reported concentrations of neurotransmitters in vivo 
are often increased as compared to those concentrations obtained using 
microdialysis (Hascup, Hascup et al. 2010).  Our MEAs offer the advantage of 
improved spatial resolution over microdialysis probes, allowing for measurements 
of synaptic spill-over (Day, Pomerleau et al. 2006).  Additionally, our probes have 
been shown to cause minimal damage compared to microdialysis probes 
(Hascup, af Bjerken et al. 2009), and only measure substances that come into 
contact with the surface of the Pt recording site (Burmeister, Moxon et al. 2000).       
Experiments in the mPFC of F344 rats (Mattinson, Burmeister et al. 2011) 
revealed glutamate resting levels of 3.7 - 4.3 µM.  These levels are increased as 
compared to our glutamate resting levels in Sprague-Dawley rats from these 
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experiments.  As both sets of these experiments were performed under urethane 
anesthesia and using MEA technology, the logical explanation for these 
differences would be the strain of the animals.  F344 rats are an in-bred strain 
typically used for aging and cancer research (Cameron, Hickman et al. 1985), 
whereas Sprague-Dawley rats are an out-bred strain commonly used in behavior 
and drug studies.  Differences in genetics may account for the marked 
differences in mPFC glutamate concentrations between these two strains.     
  Interestingly, the F344 levels are similar to the levels observed in our 
Sprague-Dawley chronically MPH-treated rats.  Although chronically-MPH 
treated rats do not vary significantly from the controls, the trend towards 
augmented glutamate levels in the MPH treatment group is apparent.  An 
increased n value could provide significant results.  As MPH is known to increase 
extracellular concentrations of dopamine (Hurd and Ungerstedt 1989; Butcher, 
Liptrot et al. 1991), it is possible that increased concentrations of dopamine 
within cortical and mesolimbic circuitry are responsible for potential increases in 
glutamate release in the mPFC.  
It should also be noted that urethane anesthesia was used in these 
experiments, and Rutherford et al. has shown that urethane administration 
significantly reduces resting levels of glutamate (Rutherford, Pomerleau et al. 
2007).  Thus, it is possible that our reported resting levels of glutamate in the 
mPFC are actually significantly higher in both the MPH and saline treated groups 
when urethane is not present, and further studies without the effects of 
anesthetics are needed. 
 
Dynamic Glutamate Signaling Parameters Are Homogenous 
Dynamic glutamate signaling parameters including peak amplitudes, T80 
values, and uptake rates were analyzed, and all parameters were found to be 
similar between chronically MPH-treated and saline-treated groups, as well as 
similar among mPFC sub-regions.  Peak amplitudes (see Table 5.1) only varied 
by 1.2 µM between the highest and lowest reported average values.  This 
indicates that KCl-evoked glutamate release in all three mPFC sub-regions is 
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relatively uniform.  Additionally, MPH did not have an effect on stimulated phasic 
glutamate release as compared to controls.  This differs from previous work by 
Stephans and Yamamoto (1995), who measured an increase in KCl-evoked 
glutamate release in the mPFC after chronic administration of methamphetamine 
(Stephans and Yamamoto 1995).  As discussed in Chapter Three, microdialysis 
studies have reported both an increase (Frantz, Harte et al. 2002) and no change 
(Welty and Shoblock 2009) in mPFC glutamate levels in response to intracranial 
KCl administration.  The rapid, phasic glutamate signal produced by KCl 
ejections cannot be measured using microdialysis due to this technique’s poor 
temporal resolution, and therefore, our results provide a better characterization of 
KCl-evoked glutamate release in the mPFC.  
Chronically MPH-treated rats’ T80 values in both the prelimbic and 
infralimbic mPFC showed a trend toward increased time for 80% of signal decay 
to occur.  These results were not significant, but the times averaged 
approximately five and four seconds for the prelimbic and infralimbic, 
respectively.  This increase in decay times may be due to drug-induced 
differences in glutamate transporter dynamics (Danbolt 2001).  Extinction from 
cocaine administration has been shown to alter EAAT binding in the infralimbic 
mPFC (Miguens, Crespo et al. 2008), however, acute and chronic amphetamine 
administration has been shown to have no effect on EAAT levels in the PFC 
(Sidiropoulou, Chao et al. 2001).  Additionally, although MPH has not been 
shown to act on the glutamate transporter (Iversen 2006), it has been linked to a 
down regulation of GLAST in the striatum (Cavaliere, Cirillo et al. 2012).  Uptake 
rates do not follow the same trend as T80 values, and remain relatively uniform 
despite differing treatments and mPFC sub-regions.    
 
Conclusions 
From this set of experiments, we can conclude that chronically MPH-
treated animals do not differ significantly from saline controls in both tonic and 
phasic measurements of glutamate in the cingulate, prelimbic, and infralimbic 
sub-regions of the mPFC.  Although not significant, resting levels of glutamate 
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trended towards increased glutamate concentrations in chronically MPH-treated 
rats in all mPFC sub-regions, and a trend of increased T80 values in the prelimbic 
and infralimbic mPFC of chronically MPH-treated rats was observed.  Further 
experiments are needed to discern whether these trends are potential sources of 
significant differences.  We did find, as predicted, significantly increased amounts 
of locomotor activity in animals chronically treated with MPH as compared to 
saline controls.  Future experiments in awake freely-moving animals would allow 
for the simultaneous comparison of MPH treatment and animal behavior, thus 
providing a better characterization of the effects of MPH treatment on glutamate 
signaling in the mPFC.    
 
Copyright © Catherine Elizabeth Mattinson 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83
Chapter Five: Figures 
 
 
Figure 5.1 Locomotor Activity Following Methylphenidate Treatment 
After the daily treatment injection, rats were placed in locomotor chambers for 
one hour (saline, n = 4; MPH, n = 5).  Distance traveled in five minute bins was 
averaged for each rat on each day.  Rats treated with MPH had significantly 
increased locomotor activity as compared to the saline controls (t(9) = 12; ****p < 
0.0001; two-tailed paired t test).  Data points are shown as averages ± SEM.      
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Figure 5.2 Glutamate Resting Levels and Peak Amplitudes in Prefrontal Cortex 
Sub-Regions 
Analyses of resting levels of glutamate levels (A) revealed similar concentrations 
between treatment groups and among sub-regions (saline, n = 4; MPH, n = 5).  
Peak amplitude measurements (B) were also fairly homogenous.    
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Figure 5.3  GlutamateT80 Values and Uptake Rates in Medial Prefrontal Cortex 
Sub-Regions 
Both T80 values (A) and uptake rates (B) showed homogeneity between chronic 
treatment groups and among sub-regions (saline, n = 4; MPH, n = 5).   
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Table 5.1 Comparison of Glutamate Signaling Parameters Between MPH 
Treated Rats and Controls 
 
Brain  
Sub-Regions 
Chronic 
Treatment
Peak Amplitudes
(µM) 
T80 Values
(s) 
Uptake Rates
(µM /s ) 
Cg1 Saline 2.6 ±  2.7 2.5 ± 0.56 1.7 ± 1.4 
MPH 2.4 ± 1.9 3.0 ± 1.4 1.1 ± 1.3 
PrL Saline 2.9 ± 1.7 4.9 ± 2.6 0.80 ± 0.47 
MPH 2.0 ± 1.6 2.9 ± 1.3 0.89 ± 1.9 
IL Saline 2.0 ± 0.71 4.0 ± 3.1 2.1 ± 2.7 
MPH 1.7 ± 1.3 2.6 ± 1.6 1.2 ± 0.92 
Phasic glutamate signaling parameters of peak amplitudes, T80 values, and 
uptake rates show similarity between the treatment conditions in each mPFC 
sub-region (mean ± SD; saline, n = 4; MPH, n = 5). 
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Chapter Six:  The Effects of Methylphenidate on Infralimbic 
Prefrontal Cortex Glutamate Signaling in the Awake Freely-Moving 
Rat 
 
Introduction 
MPH is a stimulant medication that used in the treatment of attention-
deficit hyperactivity disorder.  As a stimulant, MPH is also abused, particularly in 
the adolescent and college age populations (DeSantis, Webb et al. 2008; 
Dupont, Coleman et al. 2008; Bogle and Smith 2009; Setlik, Bond et al. 2009).  It 
has been reported that approximately 20% of children and adolescents taking 
MPH have been approached to sell, give away or trade their medication (Musser, 
Ahmann et al. 1998; Kollins, MacDonald et al. 2001).  Additionally, in human 
discriminative-stimulus studies, MPH has been shown to produce high levels of 
amphetamine- and cocaine-appropriate responding (Heishman and Henningfield 
1991; Rush, Kollins et al. 1998; Rush and Baker 2001), highlighting the subject-
perceived similarity between MPH and known stimulants of abuse.       
The infralimbic mPFC was chosen as the site of interest in these studies 
because of its involvement in drug addiction.  The infralimbic sub-region 
specifically has been shown to be critical for suppressing drug seeking behavior 
following extinction in rats (Peters, LaLumiere et al. 2008; Peters, Kalivas et al. 
2009; LaLumiere, Smith et al. 2012).  Additionally, data from our anesthetized 
chronic MPH treatment studies suggest that the infralimbic mPFC may be an 
area that differs in glutamate signaling parameters such as resting glutamate 
levels and T80 (time for 80% of a phasic signal to decay to baseline) between 
chronically MPH-treated and saline-treated rats.  Rapid, transient glutamate 
events (Hascup, Hascup et al. 2011) were also examined, as our advanced MEA 
technology offers the ability to sample glutamate signaling on a sub-second time 
scale.    
Our earlier work sought to characterize the effects of MPH on glutamate 
signaling in three sub-regions of the mPFC through a depth profile analysis.  To 
gain further insight into the effect of MPH on infralimbic glutamatergic 
transmission without the confound of anesthesia, we chronically treated rats with 
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MPH, implanted MEAs in the infralimbic mPFC for glutamate detection, and 
recorded glutamatergic neurotransmission and behavior during an MPH 
challenge dose and a cocaine challenge dose.  The challenge dose paradigm 
was used to investigate the possibility of sensitization to MPH following chronic 
treatment and a rest period, as it has been shown that behavioral responses to 
psychomotor stimulants exist long after drug treatment (Pierce and Kalivas 
1997). Thus, we hypothesized that we would see behavioral sensitization, as well 
as a sensitization of tonic and phasic glutamate signaling to MPH administration.   
 
Materials and Methods 
 
Animals 
Male Sprague-Dawley rats, aged 3-6 months were used for these 
experiments (for care, see Animals).  Following MEA implant surgery, animals 
were monitored and weighed daily.  If an animal weighed less than 80% of its 
pre-surgery body weight, recordings were not performed that day.     
 
Methylphenidate Administration 
Rats received injections for ten consecutive days.  Animals were injected 
with either MPH (10 mg/kg in saline; s.c.) or saline (s.c.), and then placed in a 
locomotor activity monitoring chamber for one hour.  Following activity 
monitoring, animals were given saline injections (s.c.) before being returned to 
their home cages.       
 
Locomotor Activity Monitoring 
After receiving the initial MPH or saline injection, animals were placed in a 
Digiscan animal activity monitoring device inside of the recording chamber.  
Multiple parameters of locomotion, including distance traveled and number of 
movements, were measured in five minute time bins over the course of one hour 
using Oasis software.  Locomotor activity was measured for the entire duration of 
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electrochemical recording sessions.  After a recording session, the recording 
chamber was cleaned with Roccal disinfectant (Pfizer, Inc., New York City, NY).   
 
Experimental Timeline  
The total length of each experiment was 20 days.  Animals received either 
MPH or saline injections for ten consecutive days, and then were given a seven 
day rest period.  During the rest period, on day 14 of the experiment, MEAs were 
implanted.  Animals were given 3 days to recover from surgery before recordings 
were started.  Recordings were performed on day 18, when rats received a MPH 
challenge dose, and on day 20, when they received a cocaine challenge dose.  
After the last recording, animals were euthanized and brains were collected.   
 
Microelectrode Array Preparation 
To optimize the MEA for chronic recordings, the MEA circuit board was 
minimized, and the MEA was epoxied to a plug/connector assembly 
(Microelectrode Array Configuration and Preparation – Modifications for Awake 
Freely-Moving Recordings).  MEAs were made selective for glutamate through 
the use of glutamate oxidase coating layers (Microelectrode Array Configuration 
and Preparation – Microelectrode Array Coatings).  For in vivo chronic 
recordings, Nafion® was used as the exclusion layer (Microelectrode Array 
Configuration and Preparation – Exclusion Layers) to prevent electroactive 
interferents from coming into contact with the Pt recording sites.  Prior to 
implantation, MEAs were calibrated in vitro (Microelectrode Array Calibrations).  
For awake freely-moving MEAs, the calibrations were performed within the 
recording chamber to best simulate the environment in which the recordings 
would take place.  After calibration, MEA ceramic tips and reference electrodes 
were soaked in phosphate buffered saline (PBS; 0.05 M) until the implantation 
surgery.           
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Microelectrode Array Implant Surgery 
MEA implant surgery procedures are described in Microelectrode Array 
Implant Surgery and Recordings – Awake Freely-Moving Surgery Procedures.  
Surgical tools were autoclaved for the first surgery of the day, and sterilized in a 
glass bead sterilizer for any subsequent surgeries.  Total time for each surgery 
was approximately one hour.  
 
Awake Freely-Moving Recordings 
All recordings were performed at 4 Hz.  For details regarding recording 
protocols, see Microelectrode Array Implant Surgery and Recordings – Awake 
Freely-Moving Recordings.  On day 18 of the experiment, rats were connected to 
their tethers outside of the recording chambers, in their home cages.  This 
allowed for the signal to baseline before injections and placement into the 
recording chamber.  After approximately one hour of baseline, the rats were 
given a saline injection and placed in the recording chamber.  At this point, the 
activity monitoring software was also started.  One hour following the saline 
injection, rats in both groups were given MPH challenge doses (10 mg/kg, s.c.).  
Recordings were performed for three hours following the challenge dose 
injections.  Animals were monitored during the recordings, and if the tether 
became tangled due to locomotor activity, the experimenter unobtrusively 
unwound the line using the swivel.  At the end of the experiment, animals were 
returned to their home cages. 
On day 20, similar procedures were followed for a cocaine challenge.  
Both the saline injection and cocaine injection (10 mg/kg) were given i.p.  
Recordings were only continued for 90 minutes after the cocaine challenge 
injection, due to the shorter half-life of cocaine.  After the experiments, animals 
were returned to their home cages, and then later sacrificed.    
 
Histology 
After the experiments, animals euthanized under heavy anesthesia and 
their brains were removed to check for MEA placements.  For details, see 
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Histology.  Animals with MEA placements outside of the infralimbic cortex were 
excluded from data analysis.   
 
Data Analysis and Statistics 
Collected data were processed using a custom Matlab®-based analysis 
package (Data Collection).  Data parameters of interest included resting levels of 
glutamate, glutamate peak amplitudes, T80 values, and uptake rates. To examine 
phasic glutamate activity, recordings were scanned using a peak finder tool with 
a threshold set at a minimum of a signal-to-noise ratio of 2.5.  A two-way 
repeated measures ANOVA was used for data analysis, with a Bonferroni post 
hoc test.  Data points more than two standard deviations away from the mean 
were excluded from analyses.  Significance was defined as p < 0.05.     
 
Results 
Chronic Treatment with Methylphenidate Increases Locomotor Activity 
After receiving a daily injection of either MPH (n = 9) or saline (n = 8), 
animals’ locomotor activity was monitored.  Significant effects were found in 
distance traveled (Figure 6.1) including effects of time (F(9,15) = 1.96; p = 0.050) 
and  treatment with MPH (F(1,15) = 110; p < 0.0001), and an interaction was also 
found to be significant (F(9,135) = 4.1; p = 0.0001).  The number of movements 
(Figure 6.1) also showed significant effects of time (F(9,15) = 2.8; p = 0.0047) 
and treatment with MPH (F(1,15) = 26; p = 0.0001).   
 
Saline Injections Before Challenge Doses Reveal Significant Effects  
On drug challenge days, saline injections were administered prior to the 
MPH or cocaine injections.  On MPH challenge days, saline injections showed a 
significant effect of time on distance traveled (Figure 6.2; F(5,12) = 15; p = 
0.0001; n = 7), while no effects were seen in number of movements (Figure 6.2).  
On cocaine challenge days, saline injections also showed a significant effect of 
time (Figure 6.8; F(5,12) = 5.8; p = 0.0002; n = 7).  Similar to MPH challenge 
days, no effects were seen in the number of movements (Figure 6.8).    
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Resting levels of glutamate following these saline injections were also 
analyzed.  On MPH challenge days, resting levels of glutamate showed a 
significant effect of time (Figure 6.3; F(7,11) = 2.3; p = 0.037; saline, n = 6; MPH, 
n = 7), and on cocaine challenge days, resting levels of glutamate showed a 
significant interaction (Figure 6.9; F(7,84) = 2.6; p = 0.017; n = 7) as well as a 
significant effect of time (F(7,12) = 2.8; p = 0.011). 
Glutamate signaling parameters including number of peaks, peak 
amplitude, T80 values, and uptake rates were calculated for saline injections on 
drug challenge days.  Following saline injections on MPH challenge days, none 
of the parameters of interest showed significant effects, indicating a relative 
uniformity of data (Figure 6.4).  On cocaine challenge days, saline injections 
resulted in a significant effect of time on number of glutamate peaks (Figure 6.10; 
F(7,12) = 2.5; p = 0.023; n = 7).  There were no effects in peak amplitudes, T80 
values, or uptake rates following saline injections on cocaine challenge days.   
 
Methylphenidate Challenge Dose Affects Locomotor Activity, Glutamate 
Resting Levels, and Phasic Glutamate Signaling 
When MPH was administered as a challenge dose, significant effects 
were found in both measures of locomotor activity (Figure 6.5).  Significant 
effects of time (F(31, 12) = 18; p < 0.0001; n = 7) and chronic treatment (F(1,12) 
= 5.5; p = 0.038) were shown, and a significant interaction was also present 
(F(31, 372) = 5.1; p < 0.0001) for distance traveled.  Number of movements also 
displayed significant effects of time (F(31,12) = 4.4;p < 0.0001; n = 7) and chronic 
treatment (F(1,12) = 9.3; p = 0.010). 
The significance found in resting levels of glutamate after MPH challenge 
dose injection includes an effect of time (Figure 6.6; F(31,12) = 7.5; p < 0.0001; n 
= 7) and an interaction (F(31, 372) = 4.2; p < 0.0001). 
Uptake rates of phasic glutamate signaling associated with an MPH 
challenge dose showed a significant interaction (Figure 6.7; F(31, 341) = 1.6; p = 
0.026; saline, n = 6; MPH, n = 7).  No significant effects or interactions were 
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found for the number of glutamate peaks, peak amplitudes, and T80 values.  A 
two-way repeated measures ANOVA was used for all analyses.    
 
Significant Effects Seen in Locomotor Activity, Glutamate Resting Levels, 
and Peak Amplitudes Following Cocaine Challenge Dose 
The administration of a cocaine challenge dose resulted in significant 
effects of time on both distance traveled (Figure 6.11; F(19,12) = 3.4; p < 0.0001; 
n = 7) and number of movements (F(19,12) = 2.9; p < 0.0001) over 90 minutes. 
Glutamate resting levels showed a significant interaction (Figure 6.12; 
F(19, 228) = 4.0; p < 0.0001; n = 7) associated with the cocaine challenge dose. 
Phasic glutamate signaling parameters including number of peaks, peak 
amplitudes, T80 values, and uptake rates (Figure 6.13) did not show any 
significant effects or interactions with the cocaine challenge dose.  A two-way 
repeated measures ANOVA was used for all analyses.    
 
Discussion 
This set of experiments illustrates the effects of chronic MPH treatment on 
locomotor behavior and glutamate signaling in the infralimbic sub-region of the 
prefrontal cortex.  These studies reveal, for the first time, the in vivo 
glutamatergic response to MPH in the awake freely-moving animal.  Challenge 
doses of MPH and cocaine were used to gain insight into possible behavioral or 
pharmacological sensitization that may have occurred following chronic treatment 
with MPH.  Data indicated the presence of behavioral sensitization (see Chapter 
5) during the chronic MPH treatment period, and revealed significant effects in 
locomotor behavior and glutamate resting levels following saline injections, MPH 
injections, and cocaine injections.     
 
Chronic MPH Treatment Significantly Increases Locomotor Activity 
 Animals were treated with an abuse-level dose of MPH for ten days as a 
chronic treatment period.  During this time, animals receiving MPH showed 
consistently increased levels of locomotor activity.  As previously discussed in 
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Chapter 5, stimulant drugs predictably produce increased amounts of locomotor 
activity following administration (Dews 1953; Smith 1965; Hughes 1972; 
Bhattacharyya, Ghosh et al. 1980), and this is attributable to the behavioral 
sensitization associated with stimulant drug administration.   It should be noted 
that on day 1 of treatment, both chronically MPH-treated and saline-treated 
animals showed similar numbers of movements.  As the number of movements 
decreased and remained stable for chronically saline-treated rats, it can be 
assumed that the increase in locomotor activity was most likely due to exploring 
a novel environment.      
 
Saline Control Injections Are Associated with Significant Effects on 
Locomotor Activity and Glutamate Resting Levels  
 After the chronic treatment period and the subsequent rest period, animals 
were given a control saline injection one hour prior to their MPH or cocaine 
challenge doses.  Animals were connected to their tethers while in their home 
cages outside of the recording chamber to ensure that the glutamate signal had 
time to baseline before any pharmacological manipulations took place.  After the 
baseline period, rats received saline injections and were placed in the recording 
chamber. 
 Both chronically MPH-treated and saline-treated animals showed similar 
significant effects of time on locomotor activity after the saline injection on day 
18, the MPH challenge dose day.  These patterns of locomotor activity between 
the two groups were surprisingly similar.  Both groups of animals started with 
distance traveled total of around 1500 cm that decreased to approximately 500 
cm, with similar slopes, over the course of 30 minutes.   As the response of the 
chronically MPH-treated animals closely matched that of the chronically saline-
treated animals, we can conclude that the injection and subsequent placement in 
the recording chamber did not lead to the behavior sensitization response 
previously seen in the MPH-treated animals during their chronic treatment period.  
On day 20, prior to cocaine administration, a saline injection was administered 
and resulted in locomotor levels slightly less than the saline injections given on 
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day 18.   It should be noted that this was the animals’ first exposure to an i.p. 
injection, and this may account for the decreased levels of locomotion as 
compared to day 18.  
 Resting levels of glutamate were recorded from the infralimbic mPFC 
during the saline injection administration on both MPH and cocaine challenge 
dose days.  On day 18, the s.c. saline injection resulted in a significant effect of 
time.  Chronically MPH-treated animals averaged glutamate resting levels of 14 
µM, and chronically saline-treated animals averaged glutamate resting levels of 
22 µM following the saline injection.  Other groups have reported glutamate 
resting level concentrations ranging from 0.15 to 1.0 µM in the mPFC of awake 
freely-moving Sprague-Dawley rats (Yamamoto and Cooperman 1994; Welty 
and Shoblock 2009; Roenker, Gudelsky et al. 2011).  The more than 20-fold 
difference between our chronically saline-treated animals’ resting levels of 
glutamate and the levels of these microdialysis studies can best be explained by 
the advanced spatial resolution of our MEAs.  The possibility of the saline 
injection itself or the change in environment from home cage to recording 
chamber being the reasons for the increased resting levels as compared to the 
microdialysis studies does not seem probable, as glutamate resting levels did not 
change significantly from pre-injection glutamate resting levels.  The 38% 
decrease in resting levels of glutamate of the chronically MPH-treated rats as 
compared to saline controls is not what we would have anticipated based on our 
anesthetized results (see Chapter 5).  As the resting levels of glutamate of the 
chronically MPH-treated rats did not change significantly following the saline 
injection, it appears that the decrease in resting levels may be due to long term 
effects of chronic MPH treatment.  In other stimulant literature, cocaine has been 
shown to significantly decrease mPFC glutamate levels during self-administration 
of the drug, while increasing dopamine levels (Ben-Shahar, Szumlinski et al. 
2012), and amphetamine has been shown to decrease excitatory glutamatergic 
transmission in the PFC (Mair and Kauer 2007).  Therefore it has been 
hypothesized that increased dopamine levels may be responsible for decreasing 
glutamate release via activation of D1 receptors in the mPFC (Abekawa, Ohmori 
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et al. 2000; Mair and Kauer 2007).  Additionally, MPH administration has been 
shown to significantly decrease synaptic active zone length in the PFC and alter 
GLAST levels in the striatum (Cavaliere, Cirillo et al. 2012).  Thus, it could also 
be possible that alterations in GLT-1 and GLAST in the mPFC are responsible for 
the observed decreased glutamate resting levels.  Taken together, these findings 
provide support for our observed decrease in resting glutamate levels in 
chronically MPH-treated rats.              
 The saline injection given prior to the cocaine challenge dose on day 20 
showed similar results to that of the saline injection given on day 18.  The 
glutamate resting levels of the chronically MPH-treated rats were comparable to 
those observed on day 18.  The significant effect of time is evident in the 
decrease in resting levels of glutamate of the chronically saline-treated rats, 
which were attenuated from 28 µM to 22 µM over the 30 minute time period.  
This decrease in resting levels associated with the saline injection may be due to 
the first exposure to an i.p. injection, which would cause stress to the animal.  
This injection was also the first injection following their previous exposure to 
MPH.  Thus, the decrease in glutamate resting levels may be a sign of 
sensitization to the effects of the MPH injection. Additionally, a significant 
interaction was observed, indicating that there is a complex relationship between 
chronic treatment and time.  Chronic treatment and time serve as independent 
variables that work together to produce effects on our measurements of 
glutamate resting levels.   
 Parameters of phasic glutamate signaling did not show any significant 
differences following the saline injection on day 18, although a significant effect 
of time on number of glutamate peaks or transients existed on day 20.  This is 
not surprising, given our anesthetized data.  Thus, it appears that the saline 
injections were not capable of influencing dynamic glutamate signaling in the 
mPFC, although they did affect tonic glutamate signaling.        
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MPH Challenge Injection 
 The administration of the MPH challenge dose resulted in significant 
effects of time and chronic treatment in both distance traveled and number of 
movements, with a significant interaction also present for distance traveled. The 
sensitized locomotor response to our MPH challenge injection from the 
chronically MPH-treated animals was apparent in the distance traveled within the 
first hour following the injection.  Within sixty minutes, we observed increased 
levels of motor activity in the chronically MPH-treated group as compared to the 
chronically saline-treated control group, followed by a plateauing of distance 
traveled by the chronically MPH-treated group and a dramatic increase in 
distance traveled by the chronically saline-treated group.  The locomotor 
sensitization seen in the chronically MPH-treated group of animals supports the 
previous findings that stimulants can induce behavioral sensitization.  However, 
the chronically saline-treated animals achieved amounts of distance traveled 
higher than those of the chronically MPH-treated animals during their chronic 
treatment period, as well as during the MPH challenge dose.  This result was 
unexpected, given that the chronically saline-treated animals were drug naïve 
until this MPH administration.   
 The resting levels of glutamate of the chronically MPH-treated rats 
following the MPH injection remained relatively constant and did not vary from 
pre-injection levels.  Following the MPH injection, chronically saline-treated rats 
showed a marked decrease in glutamate resting levels that approached the 
levels of the chronically MPH-treated rats after approximately two hours.  As 
MPH increases dopamine levels, this decrease in glutamate resting levels could 
be attributed to dopamine hyperactivity stimulating D1 receptors.    
 Dynamic glutamate signaling did not show significant effects following 
MPH administration, except in the case of uptake rates which showed a 
significant interaction.  It appears from our results that MPH administration acts 
on resting glutamate levels more so than phasic aspects of glutamate signaling.  
This makes sense in light of second messenger systems involved in D1 receptor 
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activation, which would lack the temporal resolution needed to induce changes in 
rapid, phasic glutamate signaling.    
  
 Cocaine Challenge Injection 
 Following cocaine injection administration, significant effects of time were 
seen in both distance traveled and number of movements, and behavioral 
sensitization was evident in the chronically MPH-treated animals in distance 
traveled.  Twenty minutes after cocaine injections, chronically MPH-treated 
animals peaked in distance traveled as compared to their saline counterparts.  In 
addition to behavioral sensitization, this is an example of cross sensitization, the 
increase in locomotor activity that occurs when treatment with one substance (in 
this case, MPH) leads to sensitization effects when another substance is 
presented (in this case, cocaine) (Aizenstein, Segal et al. 1990).  Cross 
sensitization has been well documented in numerous cases among MPH and 
other drugs of abuse (Schenk and Izenwasser 2002; Yang, Swann et al. 2003; 
Valvassori, Frey et al. 2007; Wooters, Neugebauer et al. 2008; Wanchoo, Swann 
et al. 2009).  Cross sensitization experiments are essential for understanding the 
likelihood of the use and/or abuse of one drug leading to the abuse of another.      
 Resting levels of glutamate after cocaine administration showed a 
significant interaction, with chronically MPH-treated animals showing a slight 
increase in resting levels, and chronically saline-treated animals showing a 
decrease in resting levels.  The decrease in resting levels could once again be 
account for by D1 activation, but the increase in glutamate resting levels in the 
chronically-MPH treated group show the opposite effect.  There has been a 
report of amphetamine increasing glutamate levels in the mPFC (Del Arco, 
Martinez et al. 1998), but this effect was not seen previously with the MPH 
challenge dose on day 18.  It could be that with the shorter half-life of cocaine as 
compared to MPH, we recorded long enough to see resting levels begin to return 
to levels closer to those of the chronically saline-treated animals. 
 Once again, no significant differences in dynamic glutamate signaling 
parameters were observed.  If the animals had received injections, and then 
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performed a task, it is possible that we may have observed differences between 
chronically MPH- and saline-treated animals, as the infralimbic mPFC has been 
implicated in working memory and extinction.  Thus, future experiments should 
include a task component to allow us to better characterize chronic treatment 
effects on phasic signaling during goal-directed behavior.      
    
Conclusions 
 This set of experiments sought to characterize glutamate signaling in the 
awake freely-moving animal following chronic treatment and subsequent 
challenge with MPH.  Our results suggest that MPH increases locomotor activity, 
in accordance with previous studies.  Additionally, chronic MPH treatment 
resulted in decreased resting levels of glutamate, and following MPH 
administration, the resting levels of chronically saline-treated animals attenuated 
to levels similar to the chronically MPH-treated animals.  This observation 
provides support for the hypothesis that increased dopamine levels lead to D1 
activation and subsequent glutamate suppression in the mPFC.  For the majority 
of the experiments, we did not observe differences in dynamic signaling 
parameters.  This may be due to the fact that we did not employ a task that 
would require rapid glutamate neurotransmission, and thus we did not see 
differences between the chronic treatment groups.  Overall, this data suggests 
that the glutamate system should not be overlooked in stimulant abuse studies, 
particularly in the infralimbic mPFC.  Further work examining the relationships 
between glutamate and dopamine signaling in the infralimbic mPFC are needed 
to fully understand the neurochemical changes associated with drug addiction.  
The studies in this chapter provide a possible target for the therapeutic treatment 
of drug addiction.      
 
Copyright © Catherine Elizabeth Mattinson 2012 
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Chapter Six: Figures 
 
Figure 6.1 Locomotor Activity During Chronic Treatment Period 
During the ten day treatment period, rats that received MPH injections (n = 9) 
showed significantly increased distance traveled (A; ***p < 0.001) and number of 
movements (B) as compared to saline controls (n = 8).  Both sets of data were 
analyzed with a two-way repeated measures ANOVA.  Data shown are mean ± 
SEM.   
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Figure 6.2  Motor Activity Decreases After Saline Injection on MPH Challenge 
Day  
After receiving a saline injection (blue arrow) and being placed into the recording 
chambers, both MPH and saline treated rats (n = 7) showed a significant effect of 
time during distance traveled (A; ***p < 0.001).  There were no differences in the 
number of movements following the injection (B).  Data were analyzed with a 
two-way repeated measures ANOVA.  Data are shown as mean ± SEM. 
10
Saline Injection - MPH Challenge Day
Distance Traveled***
0
500
1000
1500
2000 Saline
MPH
20 30
Time (min)
D
is
ta
n
ce
 T
ra
ve
le
d
 (
cm
) 
/ 
5 
m
in
10
Saline Injection - MPH Challenge Day
Number of Movements
0
20
40
60
Saline
MPH
20 30
Time (min)
N
u
m
b
er
 o
f 
M
o
ve
m
en
ts
 /
 5
 m
in
A
B
 
 
 
102
 
 
Figure 6.3 Glutamate Resting Levels Show A Significant Effect of Time After 
Saline Injection on MPH Challenge Day  
Resting levels of glutamate (saline, n = 6; MPH, n = 7) were measured following 
a saline injection (blue arrow), and analysis revealed a significant effect of time 
(*p < 0.05).  Data were analyzed using a two-way repeated measures ANOVA.  
Data are shown as mean ± SEM. 
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Figure 6.4 Phasic Glutamate Signaling Following Saline Injections on MPH 
Challenge Day 
The number of peaks (A), peak amplitudes (B), T80 values (C), and uptake rates 
(D) were examined for both MPH and saline treated rats (saline, n = 6; MPH, n = 
7) following a saline injection (blue arrow).  No significant differences were found.  
Data were analyzed using a two-way repeated measures ANOVA.  Data are 
shown as mean ± SEM.     
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Figure 6.5 Methylphenidate Injections Result in Increased Locomotor Activity 
After the administration of MPH injections (green arrow), significant effects of 
time (***p < 0.001), chronic MPH treatment (p < 0.05), and an interaction (p < 
0.001) were seen in the amount of distance traveled (A; n = 7).  The number of 
movements (B) shows significant effects of time (***p < 0.001) and chronic MPH 
treatment (p < 0.05). Data were analyzed using a two-way repeated measures 
ANOVA.  Data are shown as mean ± SEM. 
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Figure 6.6 Glutamate Resting Levels Following MPH Injections  
MPH injections (green arrow) resulted in a significant interaction (***p < 0.001) 
and a significant effect of time (***p < 0.001) between glutamate resting levels of 
saline and MPH treated rats (n = 7).   Data were analyzed using a two-way 
repeated measures ANOVA.  Data are shown as mean ± SEM. 
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Figure 6.7  Phasic Glutamate Signaling Following MPH Injections 
Following MPH injections (green arrow), rats displayed relatively homogenous 
numbers of peaks (A), peak amplitudes (B), and T80 values (C) in both saline and 
MPH treated groups (saline, n = 7 for number of peaks and peak amplitudes, n = 
6 for T80 values and uptake rates; MPH, n = 7).  There was a significant 
interaction for uptake rates (D; *p < 0.05).  Data were analyzed using a two-way 
repeated measures ANOVA.  Data are shown as mean ± SEM.   
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Figure 6.8 Locomotor Activity Following Saline Injections on Cocaine Challenge 
Day 
On the cocaine challenge day, saline and MPH treated rats (n = 7) were injected 
with saline (yellow arrow).  Data revealed a significant effect of time (***p < 
0.001) on distance traveled (A) after the injection.  This time effect was not seen 
in number of the animals’ movements (B).  Data were analyzed using a two-way 
repeated measures ANOVA.  Data are shown as mean ± SEM.         
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Figure 6.9 Glutamate Resting Levels Following Saline Injections on Cocaine 
Challenge Day 
Saline injections (yellow arrow) administered before the cocaine challenge 
resulted in a significant interaction (*p < 0.05) and a significant effect of time (*p < 
0.05) on glutamate resting levels in rats (n = 7).  Data were analyzed using a two-
way repeated measures ANOVA.  Data are shown as mean ± SEM. 
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Figure 6.10 Phasic Glutamate Signaling After Saline Injections on Cocaine 
Challenge Day 
A significant effect of time was seen in the number of peaks (A; *p < 0.05; n = 7) 
following saline injections (yellow arrow).  Other phasic glutamate signaling 
parameters such as peak amplitudes (B; n = 7), T80 values (C; saline, n = 7; 
MPH, n = 6), and uptake rates (D; saline, n = 7; MPH, n = 5) did not reach 
significance.  Data were analyzed using a two-way repeated measures ANOVA.  
Data are shown as mean ± SEM.     
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Figure 6.11 Locomotor Activity Following Cocaine Injections 
Following cocaine injections (purple arrow), significant effects of time (***p < 
0.001) were observed for both distance traveled (A) and number of movements 
(B; n = 7).  Data were analyzed using a two-way repeated measures ANOVA.  
Data are shown as mean ± SEM.     
   
Cocaine  Injection
Distance Traveled***
0
500
1000
1500
2000
Saline
MPH
30 9060-10
Time (min)
D
is
ta
n
ce
 T
ra
ve
le
d
 (
cm
) 
/ 
5 
m
in
Cocaine Injection
Number of  Movements***
0
20
40
60
80
Saline
MPH
30 9060-10
Time (min)
N
u
m
b
er
 o
f 
M
o
ve
m
en
ts
 /
 5
 m
in
A
B
 
 
 
111
 
Figure 6.12 Tonic Glutamate Levels Following Cocaine Injections 
A significant interaction (****p < 0.001; n = 7) was seen in resting glutamate 
levels following cocaine injections (purple arrow).  Data were analyzed using a 
two-way repeated measures ANOVA.  Data are shown as mean ± SEM.     
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Figure 6.13 Phasic Glutamate Signaling After Cocaine Injections 
Following cocaine injections (purple arrow), no significant effects were observed 
in the number of peaks (A; n = 7), peak amplitudes (B; n = 7), T80 values (C; 
saline, n = 7; MPH, n = 6) or uptake rates (D; saline, n = 7; MPH, n = 5).  Data 
were analyzed using a two-way repeated measures ANOVA.  Data are shown as 
mean ± SEM.        
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Chapter Seven:  Final Conclusions 
 
 There is a lack of understanding of glutamate neurochemistry in the 
medial prefrontal cortex (mPFC), despite the critical role that this brain structure 
plays in higher cognitive processes and neuropathologies.  Initially, this body of 
work characterized glutamatergic signaling in the mPFC, and from our mapping 
studies, we found that glutamate levels in the cingulate, prelimbic, and infralimbic 
mPFC were relatively uniform, as were ACh levels in these three sub-regions.  
The similarity in glutamate and ACh neurotransmission within the mPFC 
underscores a somewhat homogenized regulation of the glutamatergic and 
cholinergic systems in this brain area.   
Our awake freely moving studies in the infralimbic mPFC did not find 
evidence of circadian effects on glutamate signaling.  However, we did establish 
relationships between glutamate signaling parameters and locomotion during the 
light and dark cycles of the circadian cycle.  Importantly, we observed rapid and 
dynamic glutamate transients.  These findings support other recent studies that 
have reported this aspect of phasic glutamate signaling (Hascup, Hascup et al. 
2011; Wassum, Tolosa et al. 2012) 
Our second mapping study looked at the effects of chronic MPH treatment 
on glutamate signaling in the mPFC, and did not find that the drug had any 
significant effect on glutamate resting levels or glutamate signaling parameters.  
Locomotor monitoring did reveal behavioral sensitization, which is thought to 
model drug-induced plasticity.  Due to the effects of anesthesia on glutamate 
resting levels, we then carried out this experiment, with a challenge dose 
paradigm, in the awake freely-moving animal.    
The final study explored the effects of a challenge stimulant dose on 
glutamate neurotransmission following chronic MPH treatment in the awake 
freely-moving rat.  Once again, locomotor behavioral sensitization was observed 
during the chronic treatment period in MPH-treated animals, and we confirmed 
the presence of glutamate transients.  Significant effects were observed in 
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glutamate resting levels, although most other glutamate signaling parameters did 
not show significance.  From our data, it appears that chronic MPH treatment 
resulted in decreased glutamate resting levels, and the MPH challenge dose 
given to chronically saline-treated animals decreased resting glutamate 
concentrations to similar levels.    
Taken together, this set of experiments provides data on mPFC glutamate 
signaling to a degree never before reported, and also advances our 
understanding of the effects of chronic MPH treatment on glutamate signaling in 
the mPFC.  This is the first report of mPFC sub-regional levels of glutamate and 
ACh using MEA technology, thus providing insight into neurotransmission in the 
discreet areas of a complex brain structure involved in many aspects of cognitive 
functioning.  Additionally, the characterization of the effects of MPH on glutamate 
signaling in the mPFC eliminate the paucity of information regarding the actions 
of this drug of abuse on excitatory neurochemistry in a brain region implicated in 
higher cognitive processes.      
With the information gained from our studies, scientists have an additional 
source of in vivo glutamate concentration levels in the mPFC, as measured using 
MEA technology.  It is our hope that these data will provide insight into typical 
glutamate neurotransmission, as well as glutamate neurotransmission under the 
chronic influence of a drug of abuse.  This information can be used to help 
develop pharmacotherapies that target the glutamatergic system and improve the 
lives of drug addicts.   
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